0001193125-22-292061.txt : 20221123 0001193125-22-292061.hdr.sgml : 20221123 20221123163601 ACCESSION NUMBER: 0001193125-22-292061 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20221122 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221123 DATE AS OF CHANGE: 20221123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Frazier Lifesciences Acquisition Corp CENTRAL INDEX KEY: 0001828326 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39765 FILM NUMBER: 221416780 BUSINESS ADDRESS: STREET 1: TWO UNION SQUARE, 601 UNION STREET STREET 2: SUITE 3200 CITY: SEATTLE STATE: WA ZIP: 98101 BUSINESS PHONE: 617-570-8364 MAIL ADDRESS: STREET 1: TWO UNION SQUARE, 601 UNION STREET STREET 2: SUITE 3200 CITY: SEATTLE STATE: WA ZIP: 98101 8-K 1 d426932d8k.htm 8-K 8-K
Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-third of one redeemable warrant NASDAQ NASDAQ NASDAQ --12-31 0001828326 false 0001828326 2022-11-22 2022-11-22 0001828326 us-gaap:CapitalUnitsMember 2022-11-22 2022-11-22 0001828326 flac:ClassACommonStockSubjectToPossibleRedemptionMember 2022-11-22 2022-11-22 0001828326 us-gaap:WarrantMember 2022-11-22 2022-11-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 22, 2022

 

 

FRAZIER LIFESCIENCES ACQUISITION CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39765   98-1562203

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

  (I.R.S. Employer
Identification Number)

 

Two Union Square

601 Union St., Suite 3200

SeattleWA 98101

  98101
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (206) 621-7200

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

  

Name of each exchange

on which registered

Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-third of one redeemable warrant   FLACU    NASDAQ Capital Market LLC
Class A Ordinary Shares included as part of the units   FLAC    NASDAQ Capital Market LLC
Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50   FLACW    NASDAQ Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


INTRODUCTORY NOTE

On November 22, 2022 (the “Closing Date”), Frazier Lifesciences Acquisition Corporation, a Cayman Islands exempted company (“FLAC”), consummated the previously announced business combination (the “Business Combination”) pursuant to the terms of the Business Combination Agreement (the “Business Combination Agreement”), dated July 25, 2022, by and among FLAC, NewAmsterdam Pharma Company B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands (“Holdco”), NewAmsterdam Pharma Holding B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands (“NewAmsterdam Pharma”) and NewAmsterdam Pharma Investment Corporation, a Cayman Islands exempted company (“Merger Sub”). In connection with the Business Combination, Holdco was converted into a Dutch public limited liability company (naamloze vennootschap), thereby changing its name to NewAmsterdam Pharma Company N.V.

Beginning on November 21, 2022 (the day immediately prior to the Closing Date) and finishing on November 23, 2022 (the day immediately after the Closing Date), the following transactions occurred pursuant to the terms of the Business Combination Agreement:

 

  (i)

The shareholders of NewAmsterdam Pharma contributed all outstanding shares in the capital of NewAmsterdam Pharma to Holdco in exchange for the issuance of ordinary shares, nominal value EUR 0.12, in the share capital of Holdco (“Holdco Shares”) (the “Exchange”);

 

  (ii)

Immediately after giving effect to the Exchange, the legal form of Holdco was converted from a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) to a public limited liability company (naamloze vennootschap);

 

  (iii)

After giving effect to the Exchange, Merger Sub merged with and into FLAC (the “Merger”), with FLAC surviving the merger as a wholly owned subsidiary of Holdco (the “Surviving Company”);

 

  (iv)

In connection with the Merger, each issued and outstanding ordinary share of FLAC (each, a “FLAC Share”) was canceled and extinguished in exchange for a claim for a Holdco Share, and such claim was then contributed into Holdco against the issuance of a corresponding Holdco Share;

 

  (v)

Immediately following the Merger, each outstanding warrant to purchase a Class A ordinary share, par value $0.0001 per share, of FLAC (the “FLAC Warrants”) became a warrant to purchase one Holdco Share, on the same contractual terms (the “Holdco Warrants”);

 

  (vi)

Each NewAmsterdam Pharma option that was outstanding and unexercised (“NewAmsterdam Pharma Options”) remained outstanding, and to the extent unvested, such option will continue to vest in accordance with its applicable terms, and at the time of the Exchange, such NewAmsterdam Pharma Options became options to purchase, and will when exercised be settled in, Holdco Shares; and

 

  (viii)

On the day following the Closing Date, the Surviving Company changed its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and domesticated as a corporation incorporated under the laws of the State of Delaware (the “Domestication”).

Also on November 22, 2022, certain investors (the “PIPE Investors”) consummated the subscription of 23,460,000 Holdco Shares at $10.00 per share for an aggregate subscription price of $234.6 million, pursuant to certain subscription agreements previously entered into among the PIPE Investors, Holdco and FLAC (the “PIPE Investment”).

Holders of 4,565,862 FLAC Class A Ordinary Shares exercised their right to redeem their shares for cash in connection with the Business Combination, at a redemption price of approximately $10.09 per share, for an aggregate redemption amount of $46.1 million.

The foregoing description of the Business Combination Agreement does not purport to be complete and is qualified in its entirety by the full text of the Business Combination Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K, and incorporated herein by reference.


Item 1.01

Entry into a Material Definitive Agreement

The information set forth in the Introductory Note above is incorporated into this Item 1.01 by reference.

Warrant Assumption Agreement

Immediately prior to the consummation of the Business Combination, FLAC, Holdco, and Continental Stock Transfer & Trust Company (“Continental”) entered into a warrant assignment, assumption and amendment agreement (the “Warrant Assumption Agreement”), pursuant to which FLAC assigned to Holdco all of its rights, title, interests, liabilities and obligations in and under the Warrant Agreement, dated December 8, 2020, by and between FLAC and Continental (the “Warrant Agreement”), and the terms and conditions of such Warrant Agreement were amended and restated to, among other things, reflect the assumption of the FLAC Warrants by Holdco as described above.

The foregoing description of the Warrant Assumption Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Warrant Assumption Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and incorporated herein by reference.

 

Item 1.02

Termination of a Material Definitive Agreement

The information set forth in the Introductory Note above is incorporated into this Item 1.02 by reference.

On the Closing Date, in connection with the consummation of the Business Combination, the following material agreements of FLAC terminated in accordance with their terms: (i) that certain Investment Management Trust Agreement, dated as of December 8, 2020, by and between FLAC and Continental, pursuant to which Continental invested the proceeds of FLAC’s initial public offering in a trust account; and (ii) that certain Administrative Services Agreement, dated as of December 8, 2020, between FLAC and Frazier Lifesciences Sponsor LLC (the “Sponsor”), pursuant to which the Sponsor provided FLAC with office space, secretarial and administrative services for $10,000 per month. In addition, on the Closing Date, as a result of the entry into the Investor Rights Agreement, that certain Registration Rights Agreement, dated December 8, 2020, by and among FLAC, the Sponsor and the former holders of the Class B ordinary shares, par value $0.0001 per share, of FLAC was terminated.

 

Item 2.01

Completion of Acquisition or Disposition of Assets

The information set forth in the Introductory Note above is incorporated into this Item 2.01 by reference.

As previously announced, on November 15, 2022, the Business Combination was approved by the shareholders of FLAC at an extraordinary general meeting of shareholders (the “General Meeting”). The Merger was completed on November 22, 2022 and the Business Combination was completed on November 23, 2022 upon effectiveness of the Domestication.

On November 23, 2022, Holdco Shares and certain Holdco Warrants commenced trading on The Nasdaq Stock Market LLC (the “Nasdaq”) under the symbols “NAMS” and “NAMSW,” respectively.

 

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

The information set forth in the Introductory Note above is incorporated into this Item 3.01 by reference.

In connection with the consummation of the Business Combination, on the Closing Date, FLAC notified Nasdaq that the Business Combination had been consummated and that the outstanding FLAC Shares and FLAC Warrants had been exchanged for Holdco Shares and Holdco Warrants, respectively. On November 22, 2022, a Form 25 was filed to delist FLAC Shares, FLAC Warrants and FLAC’s units from the Nasdaq, thereby commencing the process of delisting FLAC Shares, FLAC Warrants and FLAC’s units from Nasdaq and deregistering the securities under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).


Item 3.03

Material Modification to Rights of Security Holders

The information set forth in the Introductory Note, Item 2.01 and Item 3.01 above and Item 5.01 below is incorporated into this Item 3.03 by reference.

 

Item 5.01

Changes in Control of Registrant

The information set forth in the Introductory Note and Item 2.01 above is incorporated into this Item 5.01 by reference. As a result of the consummation of the Business Combination, a change in control of FLAC occurred. Following the consummation of the Business Combination, FLAC became a direct, wholly owned subsidiary of Holdco. Pursuant to the terms of the Business Combination Agreement, FLAC appointed two directors to the board of directors of Holdco.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

The information set forth in the Introductory Note above is incorporated into this Item 5.02 by reference.

Pursuant to the Business Combination Agreement, each of FLAC’s officers and directors forthwith resigned and ceased to serve as an officer or director of FLAC with effect as of immediately before the effective time of the Merger. These resignations were not a result of any disagreement between FLAC and its officers and directors on any matter relating to FLAC’s operations, policies or practices.

Immediately following the Merger, in accordance with the terms of the Business Combination Agreement, LouFré Management B.V., the director of Merger Sub immediately prior to the Merger, was appointed as the sole director of the Surviving Company. Immediately following the Domestication, LouFré Management B.V. was replaced as the director of the Surviving Company, with Michael Davidson, Douglas Kling and Louise Kooij being appointed as the directors thereof.

In addition, immediately following the Domestication, the board of directors of the Surviving Company appointed the following individuals as officers of the Surviving Company: Michael Davidson was appointed President, Douglas Kling was appointed Vice President, Louise Kooij was appointed Treasurer, and Jim Jacobson was appointed Secretary, in each case with effect as of the effective time of the Domestication.

 

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Upon the effectiveness of the Merger, the amended and restated memorandum and articles of association of FLAC were amended in their entirety to read the same as the amended and restated memorandum and articles of association of Merger Sub as in effect immediately prior to the Effective Time, except that the name of Surviving Company remained “Frazier Lifesciences Acquisition Corporation.” The amended and restated memorandum and articles of association of FLAC are attached as Exhibit 3.1 hereto and incorporated herein by reference.

Upon the effectiveness of the Domestication, the Surviving Company adopted a new certificate of incorporation and bylaws, in replacement of the amended and restated memorandum and articles of association discussed in the paragraph immediately above. The certificate of incorporation and bylaws of the Surviving Corporation are respectively attached as Exhibits 3.2 and 3.3 hereto and incorporated herein by reference.

 

Item 7.01

Regulation FD Disclosure

On November 23, 2022, Holdco issued a press release announcing the completion of the Business Combination. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings.


Item 9.01.

Financial Statements and Exhibits.

The following exhibits are furnished as part of this report:

(d) Exhibits

 

Exhibit

No.

   Description
  2.1†    Business Combination Agreement, dated as of July 25, 2022 by and among Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Company B.V., NewAmsterdam Pharma Investment Corporation and NewAmsterdam Pharma Holding B.V. (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K/A, filed with the SEC on July 25, 2022).
  3.1    Amended and Restated Memorandum and Articles of Association of the Surviving Company.
  3.2    Certificate of Incorporation of Frazier Lifesciences Acquisition Corporation.
  3.3    Bylaws of Frazier Lifesciences Acquisition Corporation.
10.1    Warrant Assignment, Assumption and Amendment Agreement, between Continental Stock Transfer & Trust Company, NewAmsterdam Pharma Company B.V. and Frazier Lifesciences Acquisition Corporation.
99.1    Press Release dated November 23, 2022.
104    Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

The schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). Provident hereby undertakes to furnish supplementally a copy of any omitted schedule to the Securities and Exchange Commission upon its request; provided, however, that Provident may request confidential treatment for any such schedules so furnished.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 23, 2022   FRAZIER LIFESCIENCES ACQUISITION CORPORATION
    By:  

/s/ Louise Kooij

    Name:   Louise Kooij
    Title:   Treasurer
EX-3.1 2 d426932dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

THE COMPANIES ACT (AS REVISED)

OF THE CAYMAN ISLANDS

COMPANY LIMITED BY SHARES

AMENDED AND RESTATED

MEMORANDUM AND ARTICLES OF ASSOCIATION

OF

FRAZIER LIFESCIENCES ACQUISITION CORPORATION

(AS ADOPTED BY SPECIAL RESOLUTION EFFECTIVE ON 22 NOVEMBER 2022)

 

    LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


THE COMPANIES ACT (AS REVISED)

OF THE CAYMAN ISLANDS

COMPANY LIMITED BY SHARES

AMENDED AND RESTATED

MEMORANDUM OF ASSOCIATION

OF

FRAZIER LIFESCIENCES ACQUISITION CORPORATION

(AS ADOPTED BY SPECIAL RESOLUTION EFFECTIVE ON 22 NOVEMBER 2022)

 

1

The name of the Company is Frazier Lifesciences Acquisition Corporation.

 

2

The Registered Office of the Company shall be at the offices of Campbells Corporate Services Limited of Floor 4, Willow House, Cricket Square, Grand Cayman KY1-9010, Cayman Islands, or at such other place within the Cayman Islands as the Directors may decide.

 

3

The objects for which the Company is established are unrestricted and the Company shall have full power and authority to carry out any object not prohibited by the laws of the Cayman Islands.

 

4

The liability of each Member is limited to the amount unpaid on such Member’s shares.

 

5

The share capital of the Company is US$50,000 divided into 50,000 shares of a par value of US$1.00 each.

 

6

The Company has power to register by way of continuation as a body corporate limited by shares under the laws of any jurisdiction outside the Cayman Islands and to be deregistered in the Cayman Islands.

 

7

Capitalised terms that are not defined in this Memorandum of Association bear the respective meanings given to them in the Articles of Association of the Company.

 

 

    LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


THE COMPANIES ACT (AS REVISED)

OF THE CAYMAN ISLANDS

COMPANY LIMITED BY SHARES

AMENDED AND RESTATED

ARTICLES OF ASSOCIATION

OF

FRAZIER LIFESCIENCES ACQUISITION CORPORATION

(AS ADOPTED BY SPECIAL RESOLUTION EFFECTIVE ON 22 NOVEMBER 2022)

 

1

Interpretation

 

1.1

In the Articles Table A in the First Schedule to the Statute does not apply and, unless there is something in the subject or context inconsistent therewith:

 

“Articles”    means these articles of association of the Company.
“Auditor”    means the person for the time being performing the duties of auditor of the Company (if any).
“Company”    means the above named company.
“Directors”    means the directors for the time being of the Company.
“Dividend”    means any dividend (whether interim or final) resolved to be paid on Shares pursuant to the Articles.
“Electronic Record”    has the same meaning as in the Electronic Transactions Act.
“Electronic Transactions Act”    means the Electronic Transactions Act (As Revised) of the Cayman Islands.
“Member”    has the same meaning as in the Statute.
“Memorandum”    means the memorandum of association of the Company.
“Ordinary Resolution”    means a resolution passed by a simple majority of the Members as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting, and includes a unanimous written resolution. In computing the majority when a poll is demanded regard shall be had to the number of votes to which each Member is entitled by the Articles.

 

    LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


Register of Members    means the register of Members maintained in accordance with the Statute and includes (except where otherwise stated) any branch or duplicate register of Members.
Registered Office    means the registered office for the time being of the Company.
Seal    means the common seal of the Company and includes every duplicate seal.
Share    means a share in the Company and includes a fraction of a share in the Company.
Special Resolution    has the same meaning as in the Statute, and includes a unanimous written resolution.
Statute    means the Companies Act (As Revised) of the Cayman Islands.
Subscriber    means the subscriber to the Memorandum.
Treasury Share    means a Share held in the name of the Company as a treasury share in accordance with the Statute.

 

1.2

In the Articles:

 

  (a)

words importing the singular number include the plural number and vice versa;

 

  (b)

words importing the masculine gender include the feminine gender;

 

  (c)

words importing persons include corporations as well as any other legal or natural person;

 

  (d)

“written” and “in writing” include all modes of representing or reproducing words in visible form, including in the form of an Electronic Record;

 

  (e)

“shall” shall be construed as imperative and “may” shall be construed as permissive;

 

  (f)

references to provisions of any law or regulation shall be construed as references to those provisions as amended, modified, re-enacted or replaced;

 

  (g)

any phrase introduced by the terms “including”, “include”, “in particular” or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms;

 

  (h)

the term “and/or” is used to mean both “and” as well as “or.” The use of “and/or” in certain contexts in no respects qualifies or modifies the use of the terms “and” or “or” in others. The term “or” shall not be interpreted to be exclusive and the term “and” shall not be interpreted to require the conjunctive (in each case, unless the context otherwise requires);

 

  (i)

headings are inserted for reference only and shall be ignored in construing the Articles;

 

  2   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


  (j)

any requirements as to delivery under the Articles include delivery in the form of an Electronic Record;

 

  (k)

any requirements as to execution or signature under the Articles including the execution of the Articles themselves can be satisfied in the form of an electronic signature as defined in the Electronic Transactions Act;

 

  (l)

sections 8 and 19(3) of the Electronic Transactions Act shall not apply;

 

  (m)

the term “clear days” in relation to the period of a notice means that period excluding the day when the notice is received or deemed to be received and the day for which it is given or on which it is to take effect; and

 

  (n)

the term “holder” in relation to a Share means a person whose name is entered in the Register of Members as the holder of such Share.

 

2

Commencement of Business

 

2.1

The business of the Company may be commenced as soon after incorporation of the Company as the Directors shall see fit.

 

2.2

The Directors may pay, out of the capital or any other monies of the Company, all expenses incurred in or about the formation and establishment of the Company, including the expenses of registration.

 

3

Issue of Shares

 

3.1

Subject to the provisions, if any, in the Memorandum (and to any direction that may be given by the Company in general meeting) and without prejudice to any rights attached to any existing Shares, the Directors may allot, issue, grant options over or otherwise dispose of Shares (including fractions of a Share) with or without preferred, deferred or other rights or restrictions, whether in regard to Dividend or other distribution, voting, return of capital or otherwise and to such persons, at such times and on such other terms as they think proper, and may also (subject to the Statute and the Articles) vary such rights. Notwithstanding the foregoing, the Subscriber shall have the power to:

 

  (a)

issue one Share to itself;

 

  (b)

transfer that Share by an instrument of transfer to any person; and

 

  (c)

update the Register of Members in respect of the issue and transfer of that Share.

 

3.2

The Company shall not issue Shares to bearer.

 

4

Register of Members

 

4.1

The Company shall maintain or cause to be maintained the Register of Members in accordance with the Statute.

 

4.2

The Directors may determine that the Company shall maintain one or more branch registers of Members in accordance with the Statute. The Directors may also determine which register of Members shall constitute the principal register and which shall constitute the branch register or registers, and to vary such determination from time to time.

 

  3   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


5

Closing Register of Members or Fixing Record Date

 

5.1

For the purpose of determining Members entitled to notice of, or to vote at any meeting of Members or any adjournment thereof, or Members entitled to receive payment of any Dividend or other distribution, or in order to make a determination of Members for any other purpose, the Directors may provide that the Register of Members shall be closed for transfers for a stated period which shall not in any case exceed forty days.

 

5.2

In lieu of, or apart from, closing the Register of Members, the Directors may fix in advance or arrears a date as the record date for any such determination of Members entitled to notice of, or to vote at any meeting of the Members or any adjournment thereof, or for the purpose of determining the Members entitled to receive payment of any Dividend or other distribution, or in order to make a determination of Members for any other purpose.

 

5.3

If the Register of Members is not so closed and no record date is fixed for the determination of Members entitled to notice of, or to vote at, a meeting of Members or Members entitled to receive payment of a Dividend or other distribution, the date on which notice of the meeting is sent or the date on which the resolution of the Directors resolving to pay such Dividend or other distribution is passed, as the case may be, shall be the record date for such determination of Members. When a determination of Members entitled to vote at any meeting of Members has been made as provided in this Article, such determination shall apply to any adjournment thereof.

 

6

Certificates for Shares

 

6.1

A Member shall only be entitled to a share certificate if the Directors resolve that share certificates shall be issued. Share certificates representing Shares, if any, shall be in such form as the Directors may determine. Share certificates shall be signed by one or more Directors or other person authorised by the Directors. The Directors may authorise certificates to be issued with the authorised signature(s) affixed by mechanical process. All certificates for Shares shall be consecutively numbered or otherwise identified and shall specify the Shares to which they relate. All certificates surrendered to the Company for transfer shall be cancelled and subject to the Articles no new certificate shall be issued until the former certificate representing a like number of relevant Shares shall have been surrendered and cancelled.

 

6.2

The Company shall not be bound to issue more than one certificate for Shares held jointly by more than one person and delivery of a certificate to one joint holder shall be a sufficient delivery to all of them.

 

6.3

If a share certificate is defaced, worn out, lost or destroyed, it may be renewed on such terms (if any) as to evidence and indemnity and on the payment of such expenses reasonably incurred by the Company in investigating evidence, as the Directors may prescribe, and (in the case of defacement or wearing out) upon delivery of the old certificate.

 

6.4

Every share certificate sent in accordance with the Articles will be sent at the risk of the Member or other person entitled to the certificate. The Company will not be responsible for any share certificate lost or delayed in the course of delivery.

 

  4   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


7

Transfer of Shares

 

7.1

Subject to Article 3.1, Shares are transferable subject to the approval of the Directors by resolution who may, in their absolute discretion, decline to register any transfer of Shares without giving any reason. If the Directors refuse to register a transfer they shall notify the transferee within two months of such refusal.

 

7.2

The instrument of transfer of any Share shall be in writing and shall be executed by or on behalf of the transferor (and if the Directors so require, signed by or on behalf of the transferee). The transferor shall be deemed to remain the holder of a Share until the name of the transferee is entered in the Register of Members.

 

8

Redemption, Repurchase and Surrender of Shares

 

8.1

Subject to the provisions of the Statute the Company may issue Shares that are to be redeemed or are liable to be redeemed at the option of the Member or the Company. The redemption of such Shares shall be effected in such manner and upon such other terms as the Company may, by Special Resolution, determine before the issue of the Shares.

 

8.2

Subject to the provisions of the Statute, the Company may purchase its own Shares (including any redeemable Shares) in such manner and on such other terms as the Directors may agree with the relevant Member.

 

8.3

The Company may make a payment in respect of the redemption or purchase of its own Shares in any manner permitted by the Statute, including out of capital.

 

8.4

The Directors may accept the surrender for no consideration of any fully paid Share.

 

9

Treasury Shares

 

9.1

The Directors may, prior to the purchase, redemption or surrender of any Share, determine that such Share shall be held as a Treasury Share.

 

9.2

The Directors may determine to cancel a Treasury Share or transfer a Treasury Share on such terms as they think proper (including, without limitation, for nil consideration).

 

10

Variation of Rights of Shares

 

10.1

If at any time the share capital of the Company is divided into different classes of Shares, all or any of the rights attached to any class (unless otherwise provided by the terms of issue of the Shares of that class) may, whether or not the Company is being wound up, be varied without the consent of the holders of the issued Shares of that class where such variation is considered by the Directors not to have a material adverse effect upon such rights; otherwise, any such variation shall be made only with the consent in writing of the holders of not less than two thirds of the issued Shares of that class, or with the approval of a resolution passed by a majority of not less than two thirds of the votes cast at a separate meeting of the holders of the Shares of that class. For the avoidance of doubt, the Directors reserve the right, notwithstanding that any such variation may not have a material adverse effect, to obtain consent from the holders of Shares of the relevant class. To any such meeting all the provisions of the Articles relating to general meetings shall apply mutatis mutandis, except that the necessary quorum shall be one person holding or representing by proxy at least one third of the issued Shares of the class and that any holder of Shares of the class present in person or by proxy may demand a poll.

 

  5   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


10.2

For the purposes of a separate class meeting, the Directors may treat two or more or all the classes of Shares as forming one class of Shares if the Directors consider that such class of Shares would be affected in the same way by the proposals under consideration, but in any other case shall treat them as separate classes of Shares.

 

10.3

The rights conferred upon the holders of the Shares of any class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the Shares of that class, be deemed to be varied by the creation or issue of further Shares ranking pari passu therewith.

 

11

Commission on Sale of Shares

The Company may, in so far as the Statute permits, pay a commission to any person in consideration of that person subscribing or agreeing to subscribe (whether absolutely or conditionally) or procuring or agreeing to procure subscriptions (whether absolutely or conditionally) for any Shares. Such commissions may be satisfied by the payment of cash and/or the issue of fully or partly paid-up Shares. The Company may also on any issue of Shares pay such brokerage as may be lawful.

 

12

Non Recognition of Trusts

The Company shall not be bound by or compelled to recognise in any way (even when notified) any equitable, contingent, future or partial interest in any Share, or (except only as is otherwise provided by the Articles or the Statute) any other rights in respect of any Share other than an absolute right to the entirety thereof in the holder.

 

13

Lien on Shares

 

13.1

The Company shall have a first and paramount lien on all Shares (whether fully paid-up or not) registered in the name of a Member (whether solely or jointly with others) for all debts, liabilities or engagements to or with the Company (whether presently payable or not) by such Member or their estate, either alone or jointly with any other person, whether a Member or not, but the Directors may at any time declare any Share to be wholly or in part exempt from the provisions of this Article. The registration of a transfer of any such Share shall operate as a waiver of the Company’s lien thereon. The Company’s lien on a Share shall also extend to any amount payable in respect of that Share.

 

13.2

The Company may sell, in such manner as the Directors think fit, any Shares on which the Company has a lien, if a sum in respect of which the lien exists is presently payable, and is not paid within 14 clear days after notice has been received or deemed to have been received by the holder of the Shares, or to the person entitled to it in consequence of the death or bankruptcy of the holder, demanding payment and stating that if the notice is not complied with the Shares may be sold.

 

13.3

To give effect to any such sale the Directors may authorise any person to execute an instrument of transfer of the Shares sold to, or in accordance with the directions of, the purchaser. The purchaser or their nominee shall be registered as the holder of the Shares comprised in any such transfer, and they shall not be bound to see to the application of the purchase money, nor shall their title to the Shares be affected by any irregularity or invalidity in the sale or the exercise of the Company’s power of sale under the Articles.

 

 

  6   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


13.4

The net proceeds of such sale after payment of costs, shall be applied in payment of such part of the amount in respect of which the lien exists as is presently payable and any balance shall (subject to a like lien for sums not presently payable as existed upon the Shares before the sale) be paid to the person entitled to the Shares at the date of the sale.

 

14

Call on Shares

 

14.1

Subject to the terms of the allotment and issue of any Shares, the Directors may make calls upon the Members in respect of any monies unpaid on their Shares (whether in respect of par value or premium), and each Member shall (subject to receiving at least 14 clear days’ notice specifying the time or times of payment) pay to the Company at the time or times so specified the amount called on the Shares. A call may be revoked or postponed, in whole or in part, as the Directors may determine. A call may be required to be paid by instalments. A person upon whom a call is made shall remain liable for calls made upon them notwithstanding the subsequent transfer of the Shares in respect of which the call was made.

 

14.2

A call shall be deemed to have been made at the time when the resolution of the Directors authorising such call was passed.

 

14.3

The joint holders of a Share shall be jointly and severally liable to pay all calls in respect thereof.

 

14.4

If a call remains unpaid after it has become due and payable, the person from whom it is due shall pay interest on the amount unpaid from the day it became due and payable until it is paid at such rate as the Directors may determine (and in addition all expenses that have been incurred by the Company by reason of such non-payment), but the Directors may waive payment of the interest or expenses wholly or in part.

 

14.5

An amount payable in respect of a Share on issue or allotment or at any fixed date, whether on account of the par value of the Share or premium or otherwise, shall be deemed to be a call and if it is not paid all the provisions of the Articles shall apply as if that amount had become due and payable by virtue of a call.

 

14.6

The Directors may issue Shares with different terms as to the amount and times of payment of calls, or the interest to be paid.

 

14.7

The Directors may, if they think fit, receive an amount from any Member willing to advance all or any part of the monies uncalled and unpaid upon any Shares held by that Member, and may (until the amount would otherwise become payable) pay interest at such rate as may be agreed upon between the Directors and the Member paying such amount in advance.

 

14.8

No such amount paid in advance of calls shall entitle the Member paying such amount to any portion of a Dividend or other distribution payable in respect of any period prior to the date upon which such amount would, but for such payment, become payable.

 

15

Forfeiture of Shares

 

15.1

If a call or instalment of a call remains unpaid after it has become due and payable the Directors may give to the person from whom it is due not less than 14 clear days’ notice requiring payment

 

 

  7   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


  of the amount unpaid together with any interest which may have accrued and any expenses incurred by the Company by reason of such non-payment. The notice shall specify where payment is to be made and shall state that if the notice is not complied with the Shares in respect of which the call was made will be liable to be forfeited.

 

15.2

If the notice is not complied with, any Share in respect of which it was given may, before the payment required by the notice has been made, be forfeited by a resolution of the Directors. Such forfeiture shall include all Dividends, other distributions or other monies payable in respect of the forfeited Share and not paid before the forfeiture.

 

15.3

A forfeited Share may be sold, re-allotted or otherwise disposed of on such terms and in such manner as the Directors think fit and at any time before a sale, re-allotment or disposition the forfeiture may be cancelled on such terms as the Directors think fit. Where for the purposes of its disposal a forfeited Share is to be transferred to any person the Directors may authorise some person to execute an instrument of transfer of the Share in favour of that person.

 

15.4

A person any of whose Shares have been forfeited shall cease to be a Member in respect of them and shall surrender to the Company for cancellation the certificate for the Shares forfeited and shall remain liable to pay to the Company all monies which at the date of forfeiture were payable by that person to the Company in respect of those Shares together with interest at such rate as the Directors may determine, but that person’s liability shall cease if and when the Company shall have received payment in full of all monies due and payable by them in respect of those Shares.

 

15.5

A certificate in writing under the hand of one Director or officer of the Company that a Share has been forfeited on a specified date shall be conclusive evidence of the facts stated in it as against all persons claiming to be entitled to the Share. The certificate shall (subject to the execution of an instrument of transfer) constitute a good title to the Share and the person to whom the Share is sold or otherwise disposed of shall not be bound to see to the application of the purchase money, if any, nor shall their title to the Share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, sale or disposal of the Share.

 

15.6

The provisions of the Articles as to forfeiture shall apply in the case of non payment of any sum which, by the terms of issue of a Share, becomes payable at a fixed time, whether on account of the par value of the Share or by way of premium as if it had been payable by virtue of a call duly made and notified.

 

16

Transmission of Shares

 

16.1

If a Member dies the survivor or survivors (where they were a joint holder) or their legal personal representatives (where they were a sole holder), shall be the only persons recognised by the Company as having any title to the deceased Member’s Shares. The estate of a deceased Member is not thereby released from any liability in respect of any Share, for which the Member was a joint or sole holder.

 

16.2

Any person becoming entitled to a Share in consequence of the death or bankruptcy or liquidation or dissolution of a Member (or in any other way than by transfer) may, upon such evidence being produced as may be required by the Directors, elect, by a notice in writing sent by that person to the Company, either to become the holder of such Share or to have some person nominated by them registered as the holder of such Share. If they elect to have another person registered as the holder of such Share they shall sign an instrument of transfer of that Share to that person. The Directors shall, in either case, have the same right to decline or suspend registration as they would have had in the case of a transfer of the Share by the relevant Member before their death or bankruptcy or liquidation or dissolution, as the case may be.

 

  8   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


16.3

A person becoming entitled to a Share by reason of the death or bankruptcy or liquidation or dissolution of a Member (or in any other case than by transfer) shall be entitled to the same Dividends, other distributions and other advantages to which they would be entitled if they were the holder of such Share. However, they shall not, before becoming a Member in respect of a Share, be entitled in respect of it to exercise any right conferred by membership in relation to general meetings of the Company and the Directors may at any time give notice requiring any such person to elect either to be registered or to have some person nominated by them registered as the holder of the Share (but the Directors shall, in either case, have the same right to decline or suspend registration as they would have had in the case of a transfer of the Share by the relevant Member before their death or bankruptcy or liquidation or dissolution or any other case than by transfer, as the case may be). If the notice is not complied with within 90 days of being received or deemed to be received (as determined pursuant to the Articles) the Directors may thereafter withhold payment of all Dividends, other distributions, bonuses or other monies payable in respect of the Share until the requirements of the notice have been complied with.

 

17

Amendments of Memorandum and Articles of Association and Alteration of Capital

 

17.1

The Company may by Ordinary Resolution:

 

  (a)

increase its share capital by such sum as the Ordinary Resolution shall prescribe and with such rights, priorities and privileges annexed thereto, as the Company in general meeting may determine;

 

  (b)

consolidate and divide all or any of its share capital into Shares of larger amount than its existing Shares;

 

  (c)

convert all or any of its paid-up Shares into stock, and reconvert that stock into paid-up Shares of any denomination;

 

  (d)

by subdivision of its existing Shares or any of them divide the whole or any part of its share capital into Shares of smaller amount than is fixed by the Memorandum or into Shares without par value; and

 

  (e)

cancel any Shares that at the date of the passing of the Ordinary Resolution have not been taken or agreed to be taken by any person and diminish the amount of its share capital by the amount of the Shares so cancelled.

 

17.2

All new Shares created in accordance with the provisions of the preceding Article shall be subject to the same provisions of the Articles with reference to the payment of calls, liens, transfer, transmission, forfeiture and otherwise as the Shares in the original share capital.

 

17.3

Subject to the provisions of the Statute and the provisions of the Articles as regards the matters to be dealt with by Ordinary Resolution, the Company may by Special Resolution:

 

  (a)

change its name;

 

  (b)

alter or add to the Articles;

 

  9   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


  (c)

alter or add to the Memorandum with respect to any objects, powers or other matters specified therein; and

 

  (d)

reduce its share capital or any capital redemption reserve fund.

 

18

Offices and Places of Business

Subject to the provisions of the Statute, the Company may by resolution of the Directors change the location of its Registered Office. The Company may, in addition to its Registered Office, maintain such other offices or places of business as the Directors determine.

 

19

General Meetings

 

19.1

All general meetings other than annual general meetings shall be called extraordinary general meetings.

 

19.2

The Company may, but shall not (unless required by the Statute) be obliged to, in each year hold a general meeting as its annual general meeting, and shall specify the meeting as such in the notices calling it. Any annual general meeting shall be held at such time and place as the Directors shall appoint and if no other time and place is prescribed by them, it shall be held at the Registered Office on the second Wednesday in December of each year at ten o’clock in the morning. At these meetings the report of the Directors (if any) shall be presented.

 

19.3

The Directors may call general meetings, and they shall on a Members’ requisition forthwith proceed to convene an extraordinary general meeting of the Company.

 

19.4

A Members’ requisition is a requisition of Members holding at the date of deposit of the requisition not less than 10% in par value of the issued Shares which as at that date carry the right to vote at general meetings of the Company.

 

19.5

The Members’ requisition must state the objects of the meeting and must be signed by the requisitionists and deposited at the Registered Office, and may consist of several documents in like form each signed by one or more requisitionists.

 

19.6

If there are no Directors as at the date of the deposit of the Members’ requisition or if the Directors do not within 21 days from the date of the deposit of the Members’ requisition duly proceed to convene a general meeting to be held within a further 21 days, the requisitionists, or any of them representing more than one-half of the total voting rights of all of the requisitionists, may themselves convene a general meeting, but any meeting so convened shall be held no later than the day which falls three months after the expiration of the said 21 day period.

 

19.7

A general meeting convened as aforesaid by requisitionists shall be convened in the same manner as nearly as possible as that in which general meetings are to be convened by Directors.

 

20

Notice of General Meetings

 

20.1

At least five clear days’ notice shall be given of any general meeting. Every notice shall specify the place, the day and the hour of the meeting and the general nature of the business to be conducted at the general meeting and shall be given in the manner hereinafter mentioned or in such other manner if any as may be prescribed by the Company, provided that a general meeting of the Company shall, whether or

 

  10   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


  not the notice specified in this Article has been given and whether or not the provisions of the Articles regarding general meetings have been complied with, be deemed to have been duly convened if it is so agreed:

 

  (a)

in the case of an annual general meeting, by all of the Members entitled to attend and vote at the meeting; and

 

  (b)

in the case of an extraordinary general meeting, by a majority in number of the Members having a right to attend and vote at the meeting, together holding not less than 95% in par value of the Shares giving that right.

 

20.2

The accidental omission to give notice of a general meeting to, or the non receipt of notice of a general meeting by, any person entitled to receive such notice shall not invalidate the proceedings of that general meeting.

 

21

Proceedings at General Meetings

 

21.1

No business shall be transacted at any general meeting unless a quorum is present. Two Members being individuals present in person or by proxy or if a corporation or other non-natural person by its duly authorised representative or proxy shall be a quorum unless the Company has only one Member entitled to vote at such general meeting in which case the quorum shall be that one Member present in person or by proxy or (in the case of a corporation or other non-natural person) by its duly authorised representative or proxy.

 

21.2

A person may participate at a general meeting by conference telephone or other communications equipment by means of which all the persons participating in the meeting can communicate with each other. Participation by a person in a general meeting in this manner is treated as presence in person at that meeting.

 

21.3

A resolution (including a Special Resolution) in writing (in one or more counterparts) signed by or on behalf of all of the Members for the time being entitled to receive notice of and to attend and vote at general meetings (or, being corporations or other non-natural persons, signed by their duly authorised representatives) shall be as valid and effective as if the resolution had been passed at a general meeting of the Company duly convened and held.

 

21.4

If a quorum is not present within half an hour from the time appointed for the meeting to commence or if during such a meeting a quorum ceases to be present, the meeting, if convened upon a Members’ requisition, shall be dissolved and in any other case it shall stand adjourned to the same day in the next week at the same time and/or place or to such other day, time and/or place as the Directors may determine, and if at the adjourned meeting a quorum is not present within half an hour from the time appointed for the meeting to commence, the Members present shall be a quorum.

 

21.5

The Directors may, at any time prior to the time appointed for the meeting to commence, appoint any person to act as chairperson of a general meeting of the Company or, if the Directors do not make any such appointment, the chairperson, if any, of the board of Directors shall preside as chairperson at such general meeting. If there is no such chairperson, or if the chairperson shall not be present within 15 minutes after the time appointed for the meeting to commence, or is unwilling to act, the Directors present shall elect one of their number to be chairperson of the meeting.

 

  11   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


21.6

If no Director is willing to act as chairperson or if no Director is present within 15 minutes after the time appointed for the meeting to commence, the Members present shall choose one of their number to be chairperson of the meeting.

 

21.7

The chairperson may, with the consent of a meeting at which a quorum is present (and shall if so directed by the meeting) adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place.

 

21.8

When a general meeting is adjourned for 30 days or more, notice of the adjourned meeting shall be given as in the case of an original meeting. Otherwise it shall not be necessary to give any such notice of an adjourned meeting.

 

21.9

A resolution put to the vote of the meeting shall be decided on a show of hands unless before, or on the declaration of the result of, the show of hands, the chairperson demands a poll, or any other Member or Members collectively present in person or by proxy (or in the case of a corporation or other non-natural person, by its duly authorised representative or proxy) and holding at least 10% in par value of the Shares giving a right to attend and vote at the meeting demand a poll.

 

21.10

Unless a poll is duly demanded and the demand is not withdrawn a declaration by the chairperson that a resolution has been carried or carried unanimously, or by a particular majority, or lost or not carried by a particular majority, an entry to that effect in the minutes of the proceedings of the meeting shall be conclusive evidence of that fact without proof of the number or proportion of the votes recorded in favour of or against such resolution.

 

21.11

The demand for a poll may be withdrawn.

 

21.12

Except on a poll demanded on the election of a chairperson or on a question of adjournment, a poll shall be taken as the chairperson directs, and the result of the poll shall be deemed to be the resolution of the general meeting at which the poll was demanded.

 

21.13

A poll demanded on the election of a chairperson or on a question of adjournment shall be taken forthwith. A poll demanded on any other question shall be taken at such date, time and place as the chairperson of the general meeting directs, and any business other than that upon which a poll has been demanded or is contingent thereon may proceed pending the taking of the poll.

 

21.14

In the case of an equality of votes, whether on a show of hands or on a poll, the chairperson shall be entitled to a second or casting vote.

 

22

Votes of Members

 

22.1

Subject to any rights or restrictions attached to any Shares, on a show of hands every Member who (being an individual) is present in person or by proxy or, if a corporation or other non-natural person is present by its duly authorised representative or by proxy, shall have one vote and on a poll every Member present in any such manner shall have one vote for every Share of which they are the holder.

 

22.2

In the case of joint holders the vote of the senior holder who tenders a vote, whether in person or by proxy (or, in the case of a corporation or other non-natural person, by its duly authorised representative or proxy), shall be accepted to the exclusion of the votes of the other joint holders, and seniority shall be determined by the order in which the names of the holders stand in the Register of Members.

 

  12   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


22.3

A Member of unsound mind, or in respect of whom an order has been made by any court, having jurisdiction in lunacy, may vote, whether on a show of hands or on a poll, by their committee, receiver, curator bonis, or other person on such Member’s behalf appointed by that court, and any such committee, receiver, curator bonis or other person may vote by proxy.

 

22.4

No person shall be entitled to vote at any general meeting unless they are registered as a Member on the record date for such meeting nor unless all calls or other monies then payable by them in respect of Shares have been paid.

 

22.5

No objection shall be raised as to the qualification of any voter except at the general meeting or adjourned general meeting at which the vote objected to is given or tendered and every vote not disallowed at the meeting shall be valid. Any objection made in due time in accordance with this Article shall be referred to the chairperson whose decision shall be final and conclusive.

 

22.6

On a poll or on a show of hands votes may be cast either personally or by proxy (or in the case of a corporation or other non-natural person by its duly authorised representative or proxy). A Member may appoint more than one proxy or the same proxy under one or more instruments to attend and vote at a meeting. Where a Member appoints more than one proxy the instrument of proxy shall state which proxy is entitled to vote on a show of hands and shall specify the number of Shares in respect of which each proxy is entitled to exercise the related votes.

 

22.7

On a poll, a Member holding more than one Share need not cast the votes in respect of their Shares in the same way on any resolution and therefore may vote a Share or some or all such Shares either for or against a resolution and/or abstain from voting a Share or some or all of the Shares and, subject to the terms of the instrument appointing the proxy, a proxy appointed under one or more instruments may vote a Share or some or all of the Shares in respect of which they are appointed either for or against a resolution and/or abstain from voting a Share or some or all of the Shares in respect of which they are appointed.

 

23

Proxies

 

23.1

The instrument appointing a proxy shall be in writing and shall be executed under the hand of the appointor or of their attorney duly authorised in writing, or, if the appointor is a corporation or other non natural person, under the hand of its duly authorised representative. A proxy need not be a Member.

 

23.2

The Directors may, in the notice convening any meeting or adjourned meeting, or in an instrument of proxy sent out by the Company, specify the manner by which the instrument appointing a proxy shall be deposited and the place and the time (being not later than the time appointed for the commencement of the meeting or adjourned meeting to which the proxy relates) at which the instrument appointing a proxy shall be deposited. In the absence of any such direction from the Directors in the notice convening any meeting or adjourned meeting or in an instrument of proxy sent out by the Company, the instrument appointing a proxy shall be deposited physically at the Registered Office not less than 48 hours before the time appointed for the meeting or adjourned meeting to commence at which the person named in the instrument proposes to vote.

 

23.3

The chairperson may in any event at their discretion declare that an instrument of proxy shall be deemed to have been duly deposited. An instrument of proxy that is not deposited in the manner permitted, or which has not been declared to have been duly deposited by the chairperson, shall be invalid.

 

  13   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


23.4

The instrument appointing a proxy may be in any usual or common form (or such other form as the Directors may approve) and may be expressed to be for a particular meeting or any adjournment thereof or generally until revoked. An instrument appointing a proxy shall be deemed to include the power to demand or join or concur in demanding a poll.

 

23.5

Votes given in accordance with the terms of an instrument of proxy shall be valid notwithstanding the previous death or insanity of the principal or revocation of the proxy or of the authority under which the proxy was executed, or the transfer of the Share in respect of which the proxy is given unless notice in writing of such death, insanity, revocation or transfer was received by the Company at the Registered Office before the commencement of the general meeting, or adjourned meeting at which it is sought to use the proxy.

 

24

Corporate Members

Any corporation or other non-natural person which is a Member may in accordance with its constitutional documents, or in the absence of such provision by resolution of its directors or other governing body, authorise such person as it thinks fit to act as its representative at any meeting of the Company or of any class of Members, and the person so authorised shall be entitled to exercise the same powers on behalf of the corporation which they represent as the corporation could exercise if it were an individual Member.

 

25

Shares that May Not be Voted

Shares in the Company that are beneficially owned by the Company shall not be voted, directly or indirectly, at any meeting and shall not be counted in determining the total number of outstanding Shares at any given time.

 

26

Directors

There shall be a board of Directors consisting of not less than one person (exclusive of alternate Directors) provided however that the Company may by Ordinary Resolution increase or reduce the limits in the number of Directors. The first Directors of the Company may be determined in writing by, or appointed by a resolution of, the Subscriber.

 

27

Powers of Directors

 

27.1

Subject to the provisions of the Statute, the Memorandum and the Articles and to any directions given by Special Resolution, the business of the Company shall be managed by the Directors who may exercise all the powers of the Company. No alteration of the Memorandum or Articles and no such direction shall invalidate any prior act of the Directors which would have been valid if that alteration had not been made or that direction had not been given. A duly convened meeting of Directors at which a quorum is present may exercise all powers exercisable by the Directors.

 

27.2

All cheques, promissory notes, drafts, bills of exchange and other negotiable or transferable instruments and all receipts for monies paid to the Company shall be signed, drawn, accepted, endorsed or otherwise executed as the case may be in such manner as the Directors shall determine by resolution.

 

  14   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


27.3

The Directors on behalf of the Company may pay a gratuity or pension or allowance on retirement to any Director who has held any other salaried office or place of profit with the Company or to their surviving spouse, civil partner or dependants and may make contributions to any fund and pay premiums for the purchase or provision of any such gratuity, pension or allowance.

 

27.4

The Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its undertaking, property and assets (present and future) and uncalled capital or any part thereof and to issue debentures, debenture stock, mortgages, bonds and other such securities whether outright or as security for any debt, liability or obligation of the Company or of any third party.

 

28

Appointment and Removal of Directors

 

28.1

The Company may by Ordinary Resolution appoint any person to be a Director or may by Ordinary Resolution remove any Director.

 

28.2

The Directors may appoint any person to be a Director, either to fill a vacancy or as an additional Director provided that the appointment does not cause the number of Directors to exceed any number fixed by or in accordance with the Articles as the maximum number of Directors.

 

29

Vacation of Office of Director

The office of a Director shall be vacated if:

 

  (a)

the Director gives notice in writing to the Company that they resign the office of Director; or

 

  (b)

the Director is absent (for the avoidance of doubt, without being represented by proxy or an alternate Director appointed by them) from three consecutive meetings of the board of Directors without special leave of absence from the Directors, and the Directors pass a resolution that they have by reason of such absence vacated office; or

 

  (c)

the Director dies, becomes bankrupt or makes any arrangement or composition with their creditors generally; or

 

  (d)

the Director is found to be or becomes of unsound mind; or

 

  (e)

all of the other Directors (being not less than two in number) determine that the Director should be removed as a Director, either by a resolution passed by all of the other Directors at a meeting of the Directors duly convened and held in accordance with the Articles or by a resolution in writing signed by all of the other Directors.

 

30

Proceedings of Directors

 

30.1

The quorum for the transaction of the business of the Directors may be fixed by the Directors, and unless so fixed shall be two if there are two or more Directors, and shall be one if there is only one Director. A person who holds office as an alternate Director shall, if their appointor is not present, be counted in the quorum. A Director who also acts as an alternate Director shall, if their appointor is not present, count twice towards the quorum.

 

30.2

Subject to the provisions of the Articles, the Directors may regulate their proceedings as they think fit. Questions arising at any meeting shall be decided by a majority of votes. In the case of an

 

  15   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


  equality of votes, the chairperson shall have a second or casting vote. A Director who is also an alternate Director shall be entitled in the absence of their appointor to a separate vote on behalf of their appointor in addition to their own vote.

 

30.3

A person may participate in a meeting of the Directors or any committee of Directors by conference telephone or other communications equipment by means of which all the persons participating in the meeting can communicate with each other at the same time. Participation by a person in a meeting in this manner is treated as presence in person at that meeting. Unless otherwise determined by the Directors the meeting shall be deemed to be held at the place where the chairperson is located at the start of the meeting.

 

30.4

A resolution in writing (in one or more counterparts) signed by all the Directors or all the members of a committee of the Directors or, in the case of a resolution in writing relating to the removal of any Director or the vacation of office by any Director, all of the Directors other than the Director who is the subject of such resolution (an alternate Director being entitled to sign such a resolution on behalf of their appointor and if such alternate Director is also a Director, being entitled to sign such resolution both on behalf of their appointor and in their capacity as a Director) shall be as valid and effectual as if it had been passed at a meeting of the Directors, or committee of Directors as the case may be, duly convened and held.

 

30.5

A Director or alternate Director may, or other officer of the Company on the direction of a Director or alternate Director shall, call a meeting of the Directors by at least two days’ notice in writing to every Director and alternate Director which notice shall set forth the general nature of the business to be considered unless notice is waived by all the Directors (or their alternates) either at, before or after the meeting is held. To any such notice of a meeting of the Directors all the provisions of the Articles relating to the giving of notices by the Company to the Members shall apply mutatis mutandis.

 

30.6

The continuing Directors (or a sole continuing Director, as the case may be) may act notwithstanding any vacancy in their body, but if and so long as their number is reduced below the number fixed by or pursuant to the Articles as the necessary quorum of Directors the continuing Directors or Director may act for the purpose of increasing the number of Directors to be equal to such fixed number, or of summoning a general meeting of the Company, but for no other purpose.

 

30.7

The Directors may elect a chairperson of their board and determine the period for which they are to hold office; but if no such chairperson is elected, or if at any meeting the chairperson is not present within five minutes after the time appointed for the meeting to commence, the Directors present may choose one of their number to be chairperson of the meeting.

 

30.8

All acts done by any meeting of the Directors or of a committee of the Directors (including any person acting as an alternate Director) shall, notwithstanding that it is afterwards discovered that there was some defect in the appointment of any Director or alternate Director, and/or that they or any of them were disqualified, and/or had vacated their office and/or were not entitled to vote, be as valid as if every such person had been duly appointed and/or not disqualified to be a Director or alternate Director and/or had not vacated their office and/or had been entitled to vote, as the case may be.

 

30.9

A Director but not an alternate Director may be represented at any meetings of the board of Directors by a proxy appointed in writing by that Director. The proxy shall count towards the quorum and the vote of the proxy shall for all purposes be deemed to be that of the appointing Director.

 

  16   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


31

Presumption of Assent

A Director or alternate Director who is present at a meeting of the board of Directors at which action on any Company matter is taken shall be presumed to have assented to the action taken unless their dissent shall be entered in the minutes of the meeting or unless they shall file their written dissent from such action with the person acting as the chairperson or secretary of the meeting before the adjournment thereof or shall forward such dissent by registered post to such person immediately after the adjournment of the meeting. Such right to dissent shall not apply to a Director or alternate Director who voted in favour of such action.

 

32

Directors’ Interests

 

32.1

A Director or alternate Director may hold any other office or place of profit under the Company (other than the office of Auditor) in conjunction with their office of Director for such period and on such terms as to remuneration and otherwise as the Directors may determine.

 

32.2

A Director or alternate Director may act on their own or by, through or on behalf of their firm in a professional capacity for the Company and they or their firm shall be entitled to remuneration for professional services as if they were not a Director or alternate Director.

 

32.3

A Director or alternate Director may be or become a director or other officer of or otherwise interested in any company promoted by the Company or in which the Company may be interested as a shareholder, a contracting party or otherwise, and no such Director or alternate Director shall be accountable to the Company for any remuneration or other benefits received by them as a director or officer of, or from their interest in, such other company.

 

32.4

No person shall be disqualified from the office of Director or alternate Director or prevented by such office from contracting with the Company, either as vendor, purchaser or otherwise, nor shall any such contract or any contract or transaction entered into by or on behalf of the Company in which any Director or alternate Director shall be in any way interested be or be liable to be avoided, nor shall any Director or alternate Director so contracting or being so interested be liable to account to the Company for any profit realised by or arising in connection with any such contract or transaction by reason of such Director or alternate Director holding office or of the fiduciary relationship thereby established. A Director (or their alternate Director in their absence) shall be at liberty to vote in respect of any contract or transaction in which they are interested provided that the nature of the interest of any Director or alternate Director in any such contract or transaction shall be disclosed by them at or prior to its consideration and any vote thereon.

 

32.5

A general notice that a Director or alternate Director is a shareholder, director, officer or employee of any specified firm or company and is to be regarded as interested in any transaction with such firm or company shall be sufficient disclosure for the purposes of voting on a resolution in respect of a contract or transaction in which they have an interest, and after such general notice it shall not be necessary to give special notice relating to any particular transaction.

 

33

Minutes

The Directors shall cause minutes to be made in books kept for the purpose of recording all appointments of officers made by the Directors, all proceedings at meetings of the Company or the holders of any class of Shares and of the Directors, and of committees of the Directors, including the names of the Directors or alternate Directors present at each meeting.

 

  17   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


34

Delegation of Directors’ Powers

 

34.1

The Directors may delegate any of their powers, authorities and discretions, including the power to sub-delegate, to any committee consisting of one or more Directors. They may also delegate to any managing director or any Director holding any other executive office such of their powers, authorities and discretions as they consider desirable to be exercised by that Director, provided that an alternate Director may not act as managing director and the appointment of a managing director shall be revoked forthwith if they cease to be a Director. Any such delegation may be made subject to any conditions the Directors may impose and either collaterally with or to the exclusion of their own powers and any such delegation may be revoked or altered by the Directors. Subject to any such conditions, the proceedings of a committee of Directors shall be governed by the Articles regulating the proceedings of Directors, so far as they are capable of applying.

 

34.2

The Directors may establish any committees, local boards or agencies or appoint any person to be a manager or agent for managing the affairs of the Company and may appoint any person to be a member of such committees, local boards or agencies. Any such appointment may be made subject to any conditions the Directors may impose, and either collaterally with or to the exclusion of their own powers and any such appointment may be revoked or altered by the Directors. Subject to any such conditions, the proceedings of any such committee, local board or agency shall be governed by the Articles regulating the proceedings of Directors, so far as they are capable of applying.

 

34.3

The Directors may by power of attorney or otherwise appoint any person to be the agent of the Company on such conditions as the Directors may determine, provided that the delegation is not to the exclusion of their own powers and may be revoked by the Directors at any time.

 

34.4

The Directors may by power of attorney or otherwise appoint any company, firm, person or body of persons, whether nominated directly or indirectly by the Directors, to be the attorney or authorised signatory of the Company for such purpose and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the Directors under the Articles) and for such period and subject to such conditions as they may think fit, and any such powers of attorney or other appointment may contain such provisions for the protection and convenience of persons dealing with any such attorneys or authorised signatories as the Directors may think fit and may also authorise any such attorney or authorised signatory to delegate all or any of the powers, authorities and discretions vested in them.

 

34.5

The Directors may appoint such officers of the Company (including, for the avoidance of doubt and without limitation, any secretary) as they consider necessary on such terms, at such remuneration and to perform such duties, and subject to such provisions as to disqualification and removal as the Directors may think fit. Unless otherwise specified in the terms of their appointment an officer of the Company may be removed by resolution of the Directors or Members. An officer of the Company may vacate their office at any time if they give notice in writing to the Company that they resign their office.

 

35

Alternate Directors

 

35.1

Any Director (but not an alternate Director) may by writing appoint any other Director, or any other person willing to act, to be an alternate Director and by writing may remove from office an alternate Director so appointed by them.

 

  18   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


35.2

An alternate Director shall be entitled to receive notice of all meetings of Directors and of all meetings of committees of Directors of which their appointor is a member, to attend and vote at every such meeting at which the Director appointing them is not personally present, to sign any written resolution of the Directors, and generally to perform all the functions of their appointor as a Director in their absence.

 

35.3

An alternate Director shall cease to be an alternate Director if their appointor ceases to be a Director.

 

35.4

Any appointment or removal of an alternate Director shall be by notice to the Company signed by the Director making or revoking the appointment or in any other manner approved by the Directors.

 

35.5

Subject to the provisions of the Articles, an alternate Director shall be deemed for all purposes to be a Director and shall alone be responsible for their own acts and defaults and shall not be deemed to be the agent of the Director appointing them.

 

36

No Minimum Shareholding

The Company in general meeting may fix a minimum shareholding required to be held by a Director, but unless and until such a shareholding qualification is fixed a Director is not required to hold Shares.

 

37

Remuneration of Directors

 

37.1

The remuneration to be paid to the Directors, if any, shall be such remuneration as the Directors shall determine. The Directors shall also be entitled to be paid all travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Directors or committees of Directors, or general meetings of the Company, or separate meetings of the holders of any class of Shares or debentures of the Company, or otherwise in connection with the business of the Company or the discharge of their duties as a Director, or to receive a fixed allowance in respect thereof as may be determined by the Directors, or a combination partly of one such method and partly the other.

 

37.2

The Directors may by resolution approve additional remuneration to any Director for any services which in the opinion of the Directors go beyond that Director’s ordinary routine work as a Director. Any fees paid to a Director who is also counsel, attorney or solicitor to the Company, or otherwise serves it in a professional capacity shall be in addition to their remuneration as a Director.

 

38

Seal

 

38.1

The Company may, if the Directors so determine, have a Seal. The Seal shall only be used by the authority of the Directors or of a committee of the Directors authorised by the Directors. Every instrument to which the Seal has been affixed shall be signed by at least one person who shall be either a Director or some officer of the Company or other person appointed by the Directors for the purpose.

 

38.2

The Company may have for use in any place or places outside the Cayman Islands a duplicate Seal or Seals each of which shall be a fax of the common Seal of the Company and, if the Directors so determine, with the addition on its face of the name of every place where it is to be used.

 

  19   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


38.3

A Director or officer, representative or attorney of the Company may without further authority of the Directors affix the Seal over their signature alone to any document of the Company required to be authenticated by them under seal or to be filed with the Registrar of Companies in the Cayman Islands or elsewhere wheresoever.

 

39

Dividends, Distributions and Reserve

 

39.1

Subject to the Statute and this Article and except as otherwise provided by the rights attached to any Shares, the Directors may resolve to pay Dividends and other distributions on Shares in issue and authorise payment of the Dividends or other distributions out of the funds of the Company lawfully available therefor. A Dividend shall be deemed to be an interim Dividend unless the terms of the resolution pursuant to which the Directors resolve to pay such Dividend specifically state that such Dividend shall be a final Dividend. No Dividend or other distribution shall be paid except out of the realised or unrealised profits of the Company, out of the share premium account or as otherwise permitted by law.

 

39.2

Except as otherwise provided by the rights attached to any Shares, all Dividends and other distributions shall be paid according to the par value of the Shares that a Member holds. If any Share is issued on terms providing that it shall rank for Dividend as from a particular date, that Share shall rank for Dividend accordingly.

 

39.3

The Directors may deduct from any Dividend or other distribution payable to any Member all sums of money (if any) then payable by the Member to the Company on account of calls or otherwise.

 

39.4

The Directors may resolve that any Dividend or other distribution be paid wholly or partly by the distribution of specific assets and in particular (but without limitation) by the distribution of shares, debentures, or securities of any other company or in any one or more of such ways and where any difficulty arises in regard to such distribution, the Directors may settle the same as they think expedient and in particular may issue fractional Shares and may fix the value for distribution of such specific assets or any part thereof and may determine that cash payments shall be made to any Members upon the basis of the value so fixed in order to adjust the rights of all Members and may vest any such specific assets in trustees in such manner as may seem expedient to the Directors.

 

39.5

Except as otherwise provided by the rights attached to any Shares, Dividends and other distributions may be paid in any currency. The Directors may determine the basis of conversion for any currency conversions that may be required and how any costs involved are to be met.

 

39.6

The Directors may, before resolving to pay any Dividend or other distribution, set aside such sums as they think proper as a reserve or reserves which shall, at the discretion of the Directors, be applicable for any purpose of the Company and pending such application may, at the discretion of the Directors, be employed in the business of the Company.

 

39.7

Any Dividend, other distribution, interest or other monies payable in cash in respect of Shares may be paid by wire transfer to the holder or by cheque or warrant sent through the post directed to the registered address of the holder or, in the case of joint holders, to the registered address of the holder who is first named on the Register of Members or to such person and to such address as such holder or joint holders may in writing direct. Every such cheque or warrant shall be made payable to the order of the person to whom it is sent. Any one of two or more joint holders may give effectual receipts for any Dividends, other distributions, bonuses, or other monies payable in respect of the Share held by them as joint holders.

 

  20   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


39.8

No Dividend or other distribution shall bear interest against the Company.

 

39.9

Any Dividend or other distribution which cannot be paid to a Member and/or which remains unclaimed after six months from the date on which such Dividend or other distribution becomes payable may, in the discretion of the Directors, be paid into a separate account in the Company’s name, provided that the Company shall not be constituted as a trustee in respect of that account and the Dividend or other distribution shall remain as a debt due to the Member. Any Dividend or other distribution which remains unclaimed after a period of six years from the date on which such Dividend or other distribution becomes payable shall be forfeited and shall revert to the Company.

 

40

Capitalisation

The Directors may at any time capitalise any sum standing to the credit of any of the Company’s reserve accounts or funds (including the share premium account and capital redemption reserve fund) or any sum standing to the credit of the profit and loss account or otherwise available for distribution; appropriate such sum to Members in the proportions in which such sum would have been divisible amongst such Members had the same been a distribution of profits by way of Dividend or other distribution; and apply such sum on their behalf in paying up in full unissued Shares for allotment and distribution credited as fully paid-up to and amongst them in the proportion aforesaid. In such event the Directors shall do all acts and things required to give effect to such capitalisation, with full power given to the Directors to make such provisions as they think fit in the case of Shares becoming distributable in fractions (including provisions whereby the benefit of fractional entitlements accrue to the Company rather than to the Members concerned). The Directors may authorise any person to enter on behalf of all of the Members interested into an agreement with the Company providing for such capitalisation and matters incidental or relating thereto and any agreement made under such authority shall be effective and binding on all such Members and the Company.

 

41

Books of Account

 

41.1

The Directors shall cause proper books of account (including, where applicable, material underlying documentation including contracts and invoices) to be kept with respect to all sums of money received and expended by the Company and the matters in respect of which the receipt or expenditure takes place, all sales and purchases of goods by the Company and the assets and liabilities of the Company. Such books of account must be retained for a minimum period of five years from the date on which they are prepared. Proper books shall not be deemed to be kept if there are not kept such books of account as are necessary to give a true and fair view of the state of the Company’s affairs and to explain its transactions.

 

41.2

The Directors shall determine whether and to what extent and at what times and places and under what conditions or regulations the accounts and books of the Company or any of them shall be open to the inspection of Members not being Directors and no Member (not being a Director) shall have any right of inspecting any account or book or document of the Company except as conferred by Statute or authorised by the Directors or by the Company in general meeting.

 

41.3

The Directors may cause to be prepared and to be laid before the Company in general meeting profit and loss accounts, balance sheets, group accounts (if any) and such other reports and accounts as may be required by law.

 

  21   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


42

Audit

 

42.1

The Directors may appoint an Auditor of the Company who shall hold office on such terms as the Directors determine.

 

42.2

Every Auditor of the Company shall have a right of access at all times to the books and accounts and vouchers of the Company and shall be entitled to require from the Directors and officers of the Company such information and explanation as may be necessary for the performance of the duties of the Auditor.

 

42.3

Auditors shall, if so required by the Directors, make a report on the accounts of the Company during their tenure of office at the next annual general meeting following their appointment in the case of a company which is registered with the Registrar of Companies as an ordinary company, and at the next extraordinary general meeting following their appointment in the case of a company which is registered with the Registrar of Companies as an exempted company, and at any other time during their term of office, upon request of the Directors or any general meeting of the Members.

 

43

Notices

 

43.1

Notices shall be in writing and may be given by the Company to any Member either personally or by sending it by courier, post, telex, fax or email to such Member or to such Member’s address as shown in the Register of Members (or where the notice is given by email by sending it to the email address provided by such Member). Any notice, if posted from one country to another, is to be sent by airmail.

 

43.2

Where a notice is sent by courier, service of the notice shall be deemed to be effected by delivery of the notice to a courier company, and shall be deemed to have been received on the third day (not including Saturdays or Sundays or public holidays) following the day on which the notice was delivered to the courier. Where a notice is sent by post, service of the notice shall be deemed to be effected by properly addressing, pre paying and posting a letter containing the notice, and shall be deemed to have been received on the fifth day (not including Saturdays or Sundays or public holidays in the Cayman Islands) following the day on which the notice was posted. Where a notice is sent by telex or fax, service of the notice shall be deemed to be effected by properly addressing and sending such notice and shall be deemed to have been received on the same day that it was transmitted. Where a notice is given by email service shall be deemed to be effected by transmitting the email to the email address provided by the intended recipient and shall be deemed to have been received on the same day that it was sent, and it shall not be necessary for the receipt of the email to be acknowledged by the recipient.

 

43.3

A notice may be given by the Company to the person or persons which the Company has been advised are entitled to a Share or Shares in consequence of the death or bankruptcy of a Member in the same manner as other notices which are required to be given under the Articles and shall be addressed to them by name, or by the title of representatives of the deceased, or trustee of the bankrupt, or by any like description at the address supplied for that purpose by the persons claiming to be so entitled, or at the option of the Company by giving the notice in any manner in which the same might have been given if the death or bankruptcy had not occurred.

 

43.4

Notice of every general meeting shall be given in any manner authorised by the Articles to every holder of Shares carrying an entitlement to receive such notice on the record date for such meeting except that in the case of joint holders the notice shall be sufficient if given to the joint holder first named in the Register of Members and every person upon whom the ownership of a share

 

  22   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


  devolves because they are a legal personal representative or a trustee in bankruptcy of a Member where the Member but for their death or bankruptcy would be entitled to receive notice of the meeting, and no other person shall be entitled to receive notices of general meetings.

 

44

Winding Up

 

44.1

If the Company shall be wound up the liquidator shall apply the assets of the Company in satisfaction of creditors’ claims in such manner and order as such liquidator thinks fit. Subject to the rights attaching to any Shares, in a winding up:

 

  (a)

if the assets available for distribution amongst the Members shall be insufficient to repay the whole of the Company’s issued share capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by the Members in proportion to the par value of the Shares held by them; or

 

  (b)

if the assets available for distribution amongst the Members shall be more than sufficient to repay the whole of the Company’s issued share capital at the commencement of the winding up, the surplus shall be distributed amongst the Members in proportion to the par value of the Shares held by them at the commencement of the winding up subject to a deduction from those Shares in respect of which there are monies due, of all monies payable to the Company for unpaid calls or otherwise.

 

44.2

If the Company shall be wound up the liquidator may, subject to the rights attaching to any Shares and with the approval of a Special Resolution of the Company and any other approval required by the Statute, divide amongst the Members in kind the whole or any part of the assets of the Company (whether such assets shall consist of property of the same kind or not) and may for that purpose value any assets and determine how the division shall be carried out as between the Members or different classes of Members. The liquidator may, with the like approval, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the Members as the liquidator, with the like approval, shall think fit, but so that no Member shall be compelled to accept any asset upon which there is a liability.

 

45

Indemnity and Insurance

 

45.1

Every Director and officer of the Company (which for the avoidance of doubt, shall not include auditors of the Company), together with every former Director and former officer of the Company (each an “Indemnified Person”) shall be indemnified out of the assets of the Company against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions other than such liability (if any) that they may incur by reason of their own actual fraud or wilful default. No Indemnified Person shall be liable to the Company for any loss or damage incurred by the Company as a result (whether direct or indirect) of the carrying out of their functions unless that liability arises through the actual fraud or wilful default of such Indemnified Person. No person shall be found to have committed actual fraud or wilful default under this Article unless or until a court of competent jurisdiction shall have made a finding to that effect.

 

45.2

The Company shall advance to each Indemnified Person reasonable attorneys’ fees and other costs and expenses incurred in connection with the defence of any action, suit, proceeding or investigation involving such Indemnified Person for which indemnity will or could be sought. In connection with any advance of any expenses hereunder, the Indemnified Person shall execute an undertaking to repay the advanced amount to the Company if it shall be determined by final

 

  23   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    


  judgment or other final adjudication that such Indemnified Person was not entitled to indemnification pursuant to this Article. If it shall be determined by a final judgment or other final adjudication that such Indemnified Person was not entitled to indemnification with respect to such judgment, costs or expenses, then such party shall not be indemnified with respect to such judgment, costs or expenses and any advancement shall be returned to the Company (without interest) by the Indemnified Person.

 

45.3

The Directors, on behalf of the Company, may purchase and maintain insurance for the benefit of any Director or other officer of the Company against any liability which, by virtue of any rule of law, would otherwise attach to such person in respect of any negligence, default, breach of duty or breach of trust of which such person may be guilty in relation to the Company.

 

46

Financial Year

Unless the Directors otherwise prescribe, the financial year of the Company shall end on 31st December in each year and, following the year of incorporation, shall begin on 1st January in each year.

 

47

Transfer by Way of Continuation

If the Company is exempted as defined in the Statute, it shall, subject to the provisions of the Statute and with the approval of a Special Resolution, have the power to register by way of continuation as a body corporate under the laws of any jurisdiction outside the Cayman Islands and to be deregistered in the Cayman Islands.

 

48

Mergers and Consolidations

The Company shall have the power to merge or consolidate with one or more other constituent companies (as defined in the Statute) upon such terms as the Directors may determine and (to the extent required by the Statute) with the approval of a Special Resolution.

 

  24   LOGO         
  www.verify.gov.ky File#: 366803  

Filed: 22-Nov-2022 14:08 EST

Auth Code: E05189720486    

EX-3.2 3 d426932dex32.htm EX-3.2 EX-3.2

Exhibit 3.2

CERTIFICATE OF INCORPORATION

OF

FRAZIER LIFESCIENCES ACQUISITION CORPORATION

FIRST:     The name of the corporation is Frazier Lifesciences Acquisition Corporation (hereinafter, the “Corporation”).

SECOND:    The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, and the name of its registered agent at such address is The Corporation Trust Company.

THIRD:    The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (“DGCL”).

FOURTH:    The total number of shares of stock which the Corporation shall have authority to issue is 1,000 shares of common stock, par value $0.0001 per share.

FIFTH:     The name and mailing address of the incorporator is Sebastian Marotta, Covington & Burling LLP, One CityCenter, 850 Tenth St., N.W., Washington, D.C. 20001.

SIXTH:     The business and affairs of the Corporation shall be managed by or under the direction of the board of directors, and the directors need not be elected by ballot unless required by the bylaws of the Corporation.

SEVENTH:    In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the board of directors is expressly authorized to make, amend or repeal the bylaws or adopt new bylaws without any action on the part of the stockholders of the Corporation; provided that any by-law adopted or amended by the board of directors, and any powers thereby conferred, may be amended, altered or repealed by the stockholders of the Corporation.

EIGHTH:    To the fullest extent that the DGCL or any other applicable law permits the limitation or elimination of the liability of directors, no director of the Corporation shall be liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. No amendment to, or modification or repeal of, this Article Eighth shall adversely affect any right or protection of a director of the Corporation existing hereunder with respect to any state of facts existing or act or omission occurring, or any cause of action, suit or claim that, but for this Article Eighth, would accrue or arise, prior to such amendment, modification or repeal. If the DGCL is amended after the date of filing this Certificate of Incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

NINTH:    The Corporation reserves the right to amend and repeal any provision contained in this Certificate of Incorporation in the manner from time to time as prescribed by the laws of the State of Delaware. All rights herein conferred are granted subject to this reservation.


IN WITNESS WHEREOF, I have signed this Certificate of Incorporation on this 23rd day of November, 2022.

 

/s/ Sebastian Marotta

Name: Sebastian Marotta
Incorporator
EX-3.3 4 d426932dex33.htm EX-3.3 EX-3.3

Exhibit 3.3

BYLAWS

OF

FRAZIER LIFESCIENCES ACQUISITION CORPORATION

ARTICLE I - STOCKHOLDERS

Section 1.    Annual Meeting.

An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors (the “Board of Directors”) of Frazier Lifesciences Acquisition Corporation (the “Corporation”) shall each year fix, which date shall be no later than 13 months of the last annual meeting of stockholders or, if no such meeting has been held, the date of incorporation.

Section 2.    Special Meetings.

Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Board of Directors or the president and shall be held at such place, on such date, and at such time as they or he or she shall fix.

Section 3.    Notice of Meetings.

Notice of the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, shall be given, not less than 10 nor more than 60 days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting, except as otherwise provided herein or required by law (meaning, here and hereinafter, as required from time to time by the Delaware General Corporation Law or the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”)).

When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more than 30 days after the date for which the meeting was originally noticed, notice of the place, if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, shall be given to each stockholder in conformity herewith. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting, which record date shall not precede the date upon which the resolution fixing


the record date is adopted by the Board of Directors and, except as otherwise required by law, shall not be more than 60 nor less than 10 days before the date of such adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting. At any adjourned meeting, any business may be transacted which might have been transacted at the original meeting.

Section 4.    Quorum.

At any meeting of the stockholders, the holders of a majority of all of the shares of the stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by law. Where a separate vote by a class or classes or series is required, a majority of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. A quorum once established, shall not be broken by the subsequent withdrawal of enough votes to leave less than a quorum.

If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time. At any such adjourned meeting at which there is a quorum, any business may be transacted that might have been transacted at the meeting originally called.

Section 5.    Organization.

Such person as the Board of Directors may have designated or, in the absence of such a person, the President of the Corporation or, in his or her absence, such person as may be chosen by the holders of a majority of the shares entitled to vote who are present, in person or by proxy, shall call to order any meeting of the stockholders and act as chairman of the meeting. In the absence of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chairman of the meeting appoints.

Section 6.    Conduct of Business.

The chairman of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seem to him or her in order. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting.

Section 7.    Proxies and Voting.

At any meeting of the stockholders, every stockholder entitled to vote may vote in person or by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting. Any copy, facsimile, email or other reliable reproduction of the writing or transmission created pursuant to this paragraph may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile, email or other reproduction shall be a complete reproduction of the entire original writing or transmission.

 

- 2 -


The Corporation may, and to the extent required by law, shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting may, and to the extent required by law, shall, appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. Every vote taken by ballots shall be counted by an inspector or inspectors appointed by the chairman of the meeting.

All elections shall be determined by a plurality of the votes cast, and except as otherwise required by law, all other matters shall be determined by a majority of the votes cast affirmatively or negatively.

Section 8.    Stock List.

The officer who has charge of the stock ledger of the Corporation shall, at least 10 days before every meeting of stockholders, prepare and make a complete list of stockholders entitled to vote at any meeting of stockholders, provided, however, if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the 10th day before the meeting date, arranged in alphabetical order and showing the address of each such stockholder and the number of shares registered in his or her name. Such list shall be open to the examination of any stockholder for a period of at least 10 days prior to the meeting in the manner provided by law.

A stock list shall also be open to the examination of any stockholder during the whole time of the meeting as provided by law. This list shall presumptively determine (a) the identity of the stockholders entitled to examine such stock list and to vote at the meeting and (b) the number of shares held by each of them.

Section 9.    Consent of Stockholders in Lieu of Meeting.

Any action required to be taken at any annual or special meeting of stockholders of the Corporation, or any action which may be taken at any annual or special meeting of the stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation’s registered office shall be made by hand or by certified or registered mail, return receipt requested.

 

- 3 -


Every written consent shall bear the date of signature of each stockholder who signs the consent and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered to the Corporation, a written consent or consents signed by a sufficient number of holders to take action are delivered to the Corporation in the manner prescribed in the first paragraph of this Section. A telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxyholder, or by a person or persons authorized to act for a stockholder or proxyholder, shall be deemed to be written, signed and dated for the purposes of this Section to the extent permitted by law. Any such consent shall be delivered in accordance with Section 228(d)(1) of the Delaware General Corporation Law.

Any copy, facsimile, email or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy, facsimile, email or other reproduction shall be a complete reproduction of the entire original writing.

ARTICLE II - BOARD OF DIRECTORS

Section 1.    General Powers.

The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. The Board of Directors may adopt such rules and procedures, not inconsistent with the Certificate of Incorporation, these Bylaws, or applicable law, as it may deem proper for the conduct of its meetings and the management of the Corporation.

Section 2.    Number and Term of Office.

The number of directors who shall constitute the whole Board of Directors shall be such number as the Board of Directors shall from time to time have designated, provided that the size of the initial Board of Directors shall be equal to the number of directors elected by the Incorporator of the Corporation. Each director shall be elected for a term of the earlier of one year and until his or her successor is elected and qualified, except as otherwise provided herein or required by law.

Whenever the authorized number of directors is increased between annual meetings of the stockholders, a majority of the directors then in office shall have the power to elect such new directors for the balance of a term and until their successors are elected and qualified. Any decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then in office unless, at the time of such decrease, there shall be vacancies on the board which are being eliminated by the decrease.

Section 3.    Vacancies.

If the office of any director becomes vacant by reason of death, resignation, disqualification, removal or other cause, a majority of the directors remaining in office, although less than a quorum, may elect a successor for the unexpired term and until his or her successor is elected and qualified.

 

- 4 -


Section 4.    Regular Meetings.

Regular meetings of the Board of Directors shall be held at such place or places, on such date or dates, and at such time or times as shall have been established by the Board of Directors and publicized among all directors. A notice of each regular meeting shall not be required.

Section 5.    Special Meetings.

Special meetings of the Board of Directors may be called by one-third of the directors then in office (rounded up to the nearest whole number) or by the President and shall be held at such place, on such date, and at such time as they or he or she shall fix. Notice of the place, date, and time of each such special meeting shall be given to each director by whom it is not waived by mailing written notice not less than five days before the meeting or by facsimile, email or other electronic transmission of the same not less than 24 hours before the meeting. Unless otherwise indicated in the notice thereof, any and all business may be transacted at a special meeting.

Section 6.    Quorum.

At any meeting of the Board of Directors, a majority of the total number of the whole Board of Directors shall constitute a quorum for all purposes. If a quorum shall fail to attend any meeting, a majority of those present may adjourn the meeting to another place, date, or time, without further notice or waiver thereof.

Section 7.    Participation in Meetings By Conference Telephone.

Members of the Board of Directors, or of any committee thereof, may participate in a meeting of such Board of Directors or committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other and such participation shall constitute presence in person at such meeting.

Section 8.    Conduct of Business.

At any meeting of the Board of Directors, business shall be transacted in such order and manner as the Board of Directors may from time to time determine, and all matters shall be determined by the vote of a majority of the directors present, except as otherwise provided herein or required by law. Action may be taken by the Board of Directors without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

Section 9.    Compensation of Directors.

Directors, as such, may receive, pursuant to resolution of the Board of Directors, fixed fees and other compensation for their services as directors, including, without limitation, their services as members of committees of the Board of Directors.

 

- 5 -


Section 10.    Action Without Meeting.

Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all directors or members of such committee, as the case may be, consent thereto in writing or by electronic transmission, and the writings or electronic transmissions are filed with the minutes of proceedings of the Board of Directors or committee in accordance with applicable law.

Section 11.    Resignation.

Any director may resign at any time by notice given in writing or by electronic transmission to the Corporation. Such resignation shall take effect at the date of receipt of such notice by the Corporation or at such later time as is therein specified. A verbal resignation shall not be deemed effective until confirmed by the director in writing or by electronic transmission to the Corporation.

Section 12.    Removal.

Except as prohibited by applicable law or the Certificate of Incorporation, the stockholders entitled to vote in an election of directors may remove any director from office at any time, with or without cause, by the affirmative vote of a majority in voting power thereof.

ARTICLE III - COMMITTEES

Section 1.    Committees of the Board of Directors.

The Board of Directors may from time to time designate committees of the Board of Directors, with such lawfully delegable powers and duties as it thereby confers, to serve at the pleasure of the Board of Directors and shall, for those committees and any others provided for herein, elect a director or directors to serve as the member or members, designating, if it desires, other directors as alternate members who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of any member of any committee and any alternate member in his or her place, the member or members of the committee present at the meeting and not disqualified from voting, whether or not he or she or they constitute a quorum, may by unanimous vote appoint another member of the Board of Directors to act at the meeting in the place of the absent or disqualified member.

Section 2.    Conduct of Business.

Each committee may determine the procedural rules for meeting and conducting its business and shall act in accordance therewith, except as otherwise provided herein or required by law. Adequate provision shall be made for notice to members of all meetings; one-third of the members shall constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all matters shall be determined by a majority vote of the members present. Action may be taken by any committee without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of the proceedings of such committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

 

- 6 -


ARTICLE IV - OFFICERS

Section 1.    Generally.

The officers of the Corporation shall be elected annually by the Board of Directors and may include a president, a treasurer, one or more vice presidents, and a secretary. The Board of Directors, in its discretion, may also elect one or more vice presidents, assistant treasurers, assistant secretaries, and other officers. Any two or more offices may be held by the same person. Each officer shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal.

Section 2.    President.

The president shall have general supervision over the business of the Corporation and other duties incident to the office of president, and any other duties as may be from time to time assigned to the president by the Board of Directors and subject to the control of the Board of Directors in each case. He or she shall have power to sign all stock certificates, contracts and other instruments of the Corporation which are authorized and shall have general supervision and direction of all of the other officers, employees and agents of the Corporation.

Section 3.    Vice President.

Each vice president shall have such powers and duties as may be delegated to him or her by the Board of Directors or the president. One vice president shall be designated by the Board of Directors to perform the duties and exercise the powers of the President in the event of the President’s absence or disability.

Section 4.    Treasurer.

The Treasurer shall have the responsibility for maintaining the financial records of the Corporation. He or she shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions and of the financial condition of the Corporation. The Treasurer shall also perform such other duties as the Board of Directors may from time to time prescribe.

Section 5.    Secretary.

The Secretary shall issue all authorized notices for, and shall keep minutes of, all meetings of the stockholders and the Board of Directors. He or she shall have charge of the corporate books and shall perform such other duties as the Board of Directors may from time to time prescribe.

 

- 7 -


Section 6.    Delegation of Authority.

In case any officer is absent, or for any other reason that the Board of Directors may deem sufficient, the president or the Board of Directors may delegate for the time being the powers or duties of such officer to any other officer or to any director.

Section 7.    Removal.

Any officer of the Corporation may be removed at any time, with or without cause, by the Board of Directors.

Section 8.    Action with Respect to Securities of Other Corporations.

Unless otherwise directed by the Board of Directors, the President or any officer of the Corporation authorized by the President shall have power to vote and otherwise act on behalf of the Corporation, in person or by proxy, at any meeting of stockholders of or with respect to any action of stockholders of any other corporation in which this Corporation may hold securities and otherwise to exercise any and all rights and powers which this Corporation may possess by reason of its ownership of securities in such other corporation.

ARTICLE V - STOCK

Section 1.    Certificates of Stock.

Shares of stock of the Corporation may, but need not be, represented by certificates. Each holder of stock represented by certificates shall be entitled to request a certificate signed by, or in the name of the Corporation by, any two authorized officers of the Corporation, including the President or a Vice President, and by the Secretary or an Assistant Secretary, or the Treasurer or an Assistant Treasurer, certifying the number of shares owned by him or her. Any or all of the signatures on the certificate may be by facsimile.

Section 2.    Transfers of Stock.

Transfers of stock shall be made only upon the transfer books of the Corporation kept at an office of the Corporation or by transfer agents designated to transfer shares of the stock of the Corporation. Except where a certificate is issued in accordance with Section 4 of Article V of these Bylaws, an outstanding certificate, if one has been issued, for the number of shares involved shall be surrendered for cancellation before a new certificate, if any, is issued therefor.

Section 3.    Record Date.

In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board of Directors may, except as otherwise required by law, fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such

 

- 8 -


record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the foregoing provisions of this Section 3 at the adjourned meeting.

In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

In order that the Corporation may determine the stockholders entitled to consent to corporate action without a meeting, (including electronic transmission as permitted by law), the Board of Directors may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall be not more than ten days after the date upon which the resolution fixing the record date is adopted. If no record date has been fixed by the Board of Directors and no prior action by the Board of Directors is required by the Delaware General Corporation Law, the record date shall be the first date on which a consent setting forth the action taken or proposed to be taken is delivered to the Corporation in the manner prescribed by Article I, Section 9 hereof. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by the Delaware General Corporation Law with respect to the proposed action by consent of the stockholders without a meeting, the record date for determining stockholders entitled to consent to corporate action without a meeting shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.

Section 4.    Lost, Stolen or Destroyed Certificates.

In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the Board of Directors may establish concerning proof of such loss, theft or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.

Section 5.    Regulations.

The issue, transfer, conversion and registration of certificates of stock shall be governed by such other regulations as the Board of Directors may establish.

 

- 9 -


ARTICLE VI - NOTICES

Section 1.    Notices.

If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the Delaware General Corporation Law.

Section 2.    Waivers.

A written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in such a waiver.

ARTICLE VII - MISCELLANEOUS

Section 1.    Facsimile Signatures.

In addition to the provisions for use of facsimile signatures elsewhere specifically authorized in these Bylaws, facsimile signatures of any officer or officers of the Corporation may be used whenever and as authorized by the Board of Directors or a committee thereof.

Section 2.    Books and Records.

Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be maintained on any information storage device, method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases); provided that the records so kept can be converted into clearly legible paper form within a reasonable time, and, with respect to the stock ledger, the records so kept comply with Section 224 of the Delaware General Corporation Law. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to applicable law.

Section 3.    Corporate Seal.

The Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge of the Secretary. If and when so directed by the Board of Directors or a committee thereof, duplicates of the seal may be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer.

Section 4.    Reliance upon Books, Reports and Records.

Each director, each member of any committee designated by the Board of Directors, and each officer of the Corporation shall, in the performance of his or her duties, be fully protected in relying in good faith upon the books of account or other records of the Corporation and upon

 

- 10 -


such information, opinions, reports or statements presented to the Corporation by any of its officers or employees, or committees of the Board of Directors so designated, or by any other person as to matters which such director or committee member reasonably believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.

Section 5.    Fiscal Year.

The fiscal year of the Corporation shall begin on January 1 and end on December 31 of each year.

Section 6.    Checks, Notes, Drafts, Etc.

All checks, notes, drafts, or other orders for the payment of money of the Corporation shall be signed, endorsed, or accepted in the name of the Corporation by such officer, officers, person, or persons as from time to time may be designated by the Board of Directors or by an officer or officers authorized by the Board of Directors to make such designation.

Section 7.    Dividends.

Subject to applicable law and the Certificate of Incorporation, dividends upon the shares of capital stock of the Corporation may be declared by the Board of Directors at any regular or special meeting of the Board of Directors. Dividends may be paid in cash, in property, or in shares of the Corporation’s capital stock, unless otherwise provided by applicable law or the Certificate of Incorporation

Section 8.    Time Periods.

In applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event or that an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included.

Section 9.    Conflict with Applicable Law or Certificate of Incorporation.

These Bylaws are adopted subject to any applicable law and the Certificate of Incorporation. Whenever these Bylaws may conflict with any applicable law or the Certificate of Incorporation, such conflict shall be resolved in favor of such law or the Certificate of Incorporation

ARTICLE VIII - INDEMNIFICATION OF DIRECTORS AND OFFICERS

Section 1.    Right to Indemnification.

The Corporation shall indemnify, defend and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person (an “Indemnitee”) who was or is made, or is threatened to be made, a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a

 

- 11 -


Proceeding”), by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or an officer of the Corporation or, while a director or an officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee, member, trustee or agent of another corporation or of a partnership, joint venture, trust, nonprofit entity or other enterprise (including, but not limited to, service with respect to employee benefit plans) (any such entity, an “Other Entity”), against all liability and loss suffered (including, but not limited to, expenses (including, but not limited to, attorneys’ fees and expenses), judgments, fines and amounts paid in settlement actually and reasonably incurred by such Indemnitee in connection with such Proceeding). Notwithstanding the preceding sentence, the Corporation shall be required to indemnify an Indemnitee in connection with a Proceeding (or part thereof) commenced by such Indemnitee only if the commencement of such Proceeding (or part thereof) by the Indemnitee was authorized by the Board of Directors of the Corporation or the Proceeding (or part thereof) relates to the enforcement of the Corporation’s obligations under this Section 1 of ARTICLE VIII.

Section 2.    Right to Advancement of Expenses.

The Corporation shall to the fullest extent not prohibited by applicable law pay, on an as-incurred basis, all expenses (including, but not limited to attorneys’ fees and expenses) incurred by an Indemnitee in defending any proceeding in advance of its final disposition. Such advancement shall be unconditional, unsecured and interest free and shall be made without regard to Indemnitee’s ability to repay any expenses advanced; provided, however, that, to the extent required by law, such payment of expenses in advance of the final disposition of the Proceeding shall be made only upon receipt of an unsecured undertaking by the Indemnitee to repay all amounts advanced if it should be ultimately determined that the Indemnitee is not entitled to be indemnified under this ARTICLE VIII or otherwise.

Section 3.    Claims.

If a claim for indemnification (following the final disposition of such proceeding) or advancement of expenses under this ARTICLE VIII is not paid in full within 60 days after a written claim therefor by the Indemnitee has been received by the Corporation, the Indemnitee may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim to the fullest extent permitted by law. In any such action the Corporation shall have the burden of proving that the Indemnitee is not entitled to the requested indemnification or advancement of expenses under applicable law.

Section 4.    Insurance.

The Corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, trustee, employee, member, trustee or agent of the Corporation, or was serving at the request of the Corporation as a director, officer, trustee, employee or agent of an Other Entity, against any liability asserted against the person and incurred by the person in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power or the obligation to indemnify such person against such liability under the provisions of this ARTICLE VIII or the Delaware General Corporation Law.

 

- 12 -


Section 5.    Non-Exclusivity of Rights.

The rights conferred on any Indemnitee by this ARTICLE VIII are not exclusive of other rights arising under any bylaw, agreement, vote of directors or stockholders or otherwise, and shall inure to the benefit of the heirs and legal representatives of such Indemnitee.

Section 6.    Amounts Received from an Other Entity.

Subject to Section 7 of ARTICLE VIII, the Corporation’s obligation, if any, to indemnify or to advance expenses to any Indemnitee who was or is serving at the Corporation’s request as a director, officer, employee or agent of an Other Entity shall be reduced by any amount such Indemnitee may collect as indemnification or advancement of expenses from such Other Entity.

Section 7    Amendment or Repeal.

Any right to indemnification or to advancement of expenses of any Indemnitee arising hereunder shall not be eliminated or impaired by an amendment to or repeal of this ARTICLE VIII after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action, suit, proceeding or other matter for which indemnification or advancement of expenses is sought.

Section 8    Other Indemnification and Advancement of Expenses.

This ARTICLE VIII shall not limit the right of the Corporation, to the extent and in the manner permitted by law, to indemnify and to advance expenses to persons other than Indemnitees when and as authorized by appropriate corporate action.

Section 9    Reliance.

Indemnitees who after the date of the adoption of this ARTICLE VIII become or remain an Indemnitee described in Section 1 of ARTICLE VIII will be conclusively presumed to have relied on the rights to indemnity, advancement of expenses and other rights contained in this ARTICLE VIII in entering into or continuing the service. The rights to indemnification and to the advancement of expenses conferred in this ARTICLE VIII will apply to claims made against any Indemnitee described in Section 1 of Article VIII arising out of acts or omissions that occurred or occur either before or after the adoption of this ARTICLE VIII in respect of service as a director or officer of the corporation or other service described in Section 1 of ARTICLE VIII.

Section 10    Successful Defense.

In the event that any proceeding to which an Indemnitee is a party is resolved in any manner other than by adverse judgment against the Indemnitee (including, without limitation, settlement of such proceeding with or without payment of money or other consideration) it shall be presumed that the Indemnitee has been successful on the merits or otherwise in such proceeding for purposes of Section 145(c) of the Delaware General Corporation Law. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.

 

- 13 -


ARTICLE IX - AMENDMENTS

These Bylaws may be adopted, amended or repealed by the Board of Directors at any meeting or by the stockholders at any meeting. In the case of any such amendment or repeal of Article VIII or any section thereof, the amendment or repeal shall be subject to Article VIII, Section 7.

 

- 14 -

EX-10.1 5 d426932dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

FORM OF WARRANT

ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT

This Assignment, Assumption and Amendment Agreement (this “Agreement”) is made as of November 22, 2022, by and among Frazier Lifesciences Acquisition Corporation, a Cayman Islands exempted company (“FLAC”), NewAmsterdam Pharma Company B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands (“Holdco”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (the “Warrant Agent”).

WHEREAS, FLAC and the Warrant Agent are parties to that certain Warrant Agreement, dated as of December 8, 2020, and the form of which was filed with the United States Securities and Exchange Commission on November 20, 2020 (the “Existing Warrant Agreement”);

WHEREAS, capitalized terms used herein, but not otherwise defined, shall have the meanings given to such terms in the Existing Warrant Agreement;

WHEREAS, pursuant to the Existing Warrant Agreement, FLAC issued (i) 167,000 private placement warrants to the Sponsor (collectively, the “Private Placement Warrants”) to purchase FLAC’s Class A ordinary shares, par value $0.0001 per share (“Class A Shares”), with each Private Placement Warrant being exercisable for one Class A Share and with an exercise price of $11.50 per share, and (ii) 4,600,000 warrants as part of the units issued to public investors in the Offering (the “Public Warrants” and together with the Private Placement Warrants, the “Warrants”) to purchase Class A Shares, with each whole Public Warrant being exercisable for one Class A Share and with an exercise price of $11.50 per share;

WHEREAS, all of the Warrants are governed by the Existing Warrant Agreement;

WHEREAS, on July 25, 2022, Holdco, FLAC, NewAmsterdam Pharma Investment Corporation, a Cayman Islands exempted company (“Merger Sub”) and NewAmsterdam Pharma Holding B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands, entered into that certain Business Combination Agreement (“BCA”);

WHEREAS, pursuant to the BCA, the parties thereto agreed to enter into a business combination as part of which, among other things, Merger Sub will merge with and into FLAC, with FLAC surviving such merger as a wholly-owned subsidiary of Holdco (the “Merger”) and in such Merger, each Warrant that is outstanding immediately prior to the effective date of the Merger (as determined in accordance with the applicable terms and conditions set forth in the BCA, the “Effective Date”) shall automatically cease to represent a right to acquire Class A Shares and shall, subject to the terms and conditions set forth in the BCA and in this Agreement, automatically represent, immediately following the Effective Date, a right to acquire ordinary shares in the share capital of Holdco (“Holdco Shares”) on the same contractual terms and conditions as were in effect immediately prior to the Effective Date under the Existing Warrant Agreement (the “Warrant Exchange”);


WHEREAS, the Board of Directors of FLAC has determined that the consummation of the transactions contemplated by the BCA will constitute a Business Combination for the purposes of the Existing Warrant Agreement;

WHEREAS, the Warrant Exchange in connection with such Business Combination is permitted under Section 4.5 of the Existing Warrant Agreement and does not require the consent of any Registered Holders;

WHEREAS, Section 9.8 of the Existing Warrant Agreement provides that FLAC and the Warrant Agent may amend the Existing Warrant Agreement without the consent of any Registered Holders for the purpose of curing any ambiguity, or correcting any mistake or defective provision contained therein or adding or changing any other provisions with respect to matters or questions arising under the Existing Warrant Agreement as FLAC and the Warrant Agent may deem necessary or desirable and that FLAC and the Warrant Agent deem shall not adversely affect the interest of the Registered Holders; and

WHEREAS, in connection with the Merger and the Warrant Exchange, FLAC desires to assign all of its right, title and interest in the Existing Warrant Agreement to Holdco and Holdco wishes to accept such assignment.

NOW, THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows.

1.    Assignment and Assumption; Consent.

1.1    Assignment and Assumption. FLAC hereby assigns to Holdco all of FLAC’s right, title and interest in and to the Existing Warrant Agreement (as amended hereby) as of the Effective Date and Holdco hereby assumes, and agrees to pay, perform, satisfy and discharge in full, as the same become due, all of FLAC’s liabilities and obligations under the Existing Warrant Agreement (as amended hereby) arising from and after the Effective Date.

1.2    Consent. The Warrant Agent hereby consents to the assignment of the Existing Warrant Agreement by FLAC to Holdco pursuant to Section 1.1 hereof effective as of the Effective Date, and the assumption of the Existing Warrant Agreement by Holdco from FLAC pursuant to Section 1.1 hereof effective as of the Effective Date, and to the continuation of the Existing Warrant Agreement in full force and effect from and after the Effective Date, subject at all times to the Existing Warrant Agreement (as amended hereby) and to all of the provisions, covenants, agreements, terms and conditions of the Existing Warrant Agreement and this Agreement.

2.    Amendment of Existing Warrant Agreement. FLAC and the Warrant Agent hereby amend the Existing Warrant Agreement as provided in this Section 2, effective as of the Effective Date, and acknowledge and agree that the amendments to the Existing Warrant Agreement set forth in this Section 2 are necessary or desirable and that such amendments do not adversely affect the interests of the Registered Holders.

 

-2-


2.1    Preamble. The preamble on page one of the Existing Warrant Agreement is hereby amended by deleting “Frazier Lifesciences Acquisition Corporation, a Cayman Islands exempted company” and replacing it with “NewAmsterdam Pharma Company N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands.” As a result thereof, all references to the “Company” in the Existing Warrant Agreement shall be references to NewAmsterdam Pharma Company N.V. rather than Frazier Lifesciences Acquisition Corporation.

2.2    Reference to Holdco Shares. All references to “Ordinary Shares” or “Class A ordinary shares” in the Existing Warrant Agreement (including all Exhibits thereto) shall mean “ordinary shares in the share capital of Holdco.”

2.3    Exercise Period. For purposes of the determination of the Exercise Period pursuant to Section 3.2 of the Existing Warrant Agreement as a result of the Merger, references to “the date on which the Company completes its initial Business Combination” shall be references to the “Final Closing Date,” as such term is defined in the BCA.

2.4    Notice. The address for notices to the Company set forth in Section 9.2 of the Existing Warrant Agreement is hereby amended and restated in its entirety as follows:

Gooimeer 2-35

1411 DC Naarden

The Netherlands

Attention: Louise Kooij

Email: louise.kooij@newamsterdampharma.com

3.    Miscellaneous Provisions.

3.1    Effectiveness of Warrant. Each of the parties hereto acknowledges and agrees that the effectiveness of this Agreement shall be expressly subject to the occurrence of the Merger and shall automatically be terminated and shall be null and void if the BCA shall be terminated for any reason.

3.2    Successors. All the covenants and provisions of this Agreement by or for the benefit of Holdco or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns.

3.3    Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

3.4    Applicable Law. The validity, interpretation and performance of this Agreement shall be governed in all respects by the laws of the State of New York, without giving effect to conflict of law principles that would result in the application of the substantive laws of another jurisdiction. The parties hereby agree that any action, proceeding or claim against a party

 

-3-


arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the parties hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.

3.5    Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the registered holder of any Warrant. The Warrant Agent may require any such holder to submit his Warrant for inspection by it.

3.6    Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

3.7    Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.

3.8    Entire Agreement. This Agreement and the Existing Warrant Agreement, as modified by this Agreement, constitutes the entire understanding of the parties and supersedes all prior agreements, understandings, arrangements, promises and commitments, whether written or oral, express or implied, relating to the subject matter hereof, and all such prior agreements, understandings, arrangements, promises and commitments are hereby canceled and terminated.

[Remainder of page intentionally left blank.]

 

-4-


IN WITNESS WHEREOF, FLAC, Holdco and the Warrant Agent have duly executed this Agreement, all as of the date first written above.

 

FRAZIER LIFESCIENCES ACQUISITION CORPORATION
By:  

/s/ James N. Topper

Name:   James N. Topper
Title:   Chief Executive Officer
NEWAMSTERDAM PHARMA COMPANY B.V.
By:  

/s/ Michael Davidson

Name:   Michael Davidson
Title:   Chief Executive Officer
CONTINENTAL STOCK TRANSFER & TRUST COMPANY
By:  

/s/ Margaret B. Lloyd

Name:   Margaret B. Lloyd
Title:   Vice President

[Signature Page to Warrant Assignment, Assumption and Amendment Agreement]

EX-99.1 6 d426932dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients

Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on November 22, 2022 —

— Closed concurrent, oversubscribed and upsized approximately $235 million private investment in public equity (“PIPE”), led by Frazier Healthcare Partners and Bain Capital Life Sciences —

— Gross proceeds from the transactions totaled approximately $328 million, combining approximately $93 million from the former FLAC trust account (reflecting a final redemption rate of approximately 32 percent) and the concurrent PIPE financing; expected to extend cash runway through 2026, beyond all expected Phase 3 readouts for cardiovascular disease, including PREVAIL CVOT study —

— Listed company to be named NewAmsterdam Pharma Company N.V. —

— Ordinary shares and warrants to commence trading on the Nasdaq Capital Market under the ticker symbols “NAMS” and “NAMSW,” respectively on November 23 –

Naarden, the Netherlands and Miami, USA; November 23, 2022 – NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced the closing of its business combination with Frazier Lifesciences Acquisition Corporation (Nasdaq:FLAC), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners. The ordinary shares and warrants of NewAmsterdam are expected to commence trading on the Nasdaq Capital Market under the ticker symbols “NAMS” and “NAMSW,” respectively, on November 23, 2022. The shareholders of FLAC approved the transaction on November 15, 2022, following approval by NewAmsterdam shareholders. NewAmsterdam’s existing management team, including Chief Executive Officer, Michael Davidson, M.D., will lead the combined company.

Proceeds from this transaction were approximately $328 million, prior to deducting transaction expenses, comprising approximately $93 million in funds from the former FLAC trust account and approximately $235 million from the concurrent, oversubscribed PIPE financing, which was co-led by Frazier Healthcare Partners and Bain Capital Life Sciences. The Company’s cash balance, after the transaction and excluding the transaction fees, is approximately $490 million, which the Company believes will be sufficient to fund operations through 2026, beyond the readout of its three ongoing Phase 3 trials, BROADWAY, BROOKLYN and PREVAIL. BROADWAY is a Phase 3 trial designed to evaluate the effect of obicetrapib on top of maximally tolerated lipid-lowering therapy in patients with established atherosclerotic cardiovascular disease. BROOKLYN is a Phase 3 trial designed to evaluate the effect of obicetrapib on LDL-C levels in patients with heterozygous familial hypercholesterolemia as an adjunct to maximally tolerated lipid-lowering therapy. PREVAIL is a cardiovascular outcomes trial in patients with a history of atherosclerotic cardiovascular disease with inadequately controlled LDL-C despite treatment with maximally tolerated lipid-modifying therapies. The Company expects to announce data from both BROADWAY and BROOKLYN in 2024, and from the PREVAIL CVOT study in 2026. NewAmsterdam is also evaluating obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, from which data are expected in 2023.

“At NewAmsterdam, we are passionate about delivering transformative oral therapies to people living with major cardiometabolic diseases around the world,” said Dr. Davidson. “Following the close of this transaction, we are well-positioned to execute on this vision, with late-stage trials ongoing across the globe, a leading pharmaceutical partner to support commercialization efforts in Europe, if our product candidate is approved, and what we believe to be sufficient capital to fund our business through all expected key Phase 3 data readouts for cardiovascular disease. I want to thank FLAC and its shareholders, as well as our new and existing investors, for their confidence in the NewAmsterdam team and in obicetrapib. I look forward to working with my colleagues to deliver the promise of obicetrapib to the millions of people in need of an effective and convenient LDL-C lowering therapy that can be used as an adjunct to statin therapy.”


“We believe NewAmsterdam is poised to significantly improve the treatment of cardiovascular disease by providing an oral, low-dose and once-daily CETP inhibitor with the potential to help many more patients achieve their LDL-C goals and, ultimately, avoid major adverse cardiac events,” said James Topper, M.D., Ph.D., Managing Partner at Frazier Healthcare Partners, former Chairman of the Board of Directors and Chief Executive Officer of FLAC and director of the Company. “We are delighted to support NewAmsterdam as it enters the public markets, and look forward to many more years of productive collaboration as we partner with Michael and his team to advance obicetrapib toward potential commercialization.”

Summary of Transaction

On July 25, 2022, NewAmsterdam, a privately held biotechnology company, entered into a definitive business combination agreement with FLAC, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, that was created with the purpose of merging with a company that has the potential to both develop transformative therapies for patients in need and deliver significant returns to its investors.

In the transaction, the Company received gross proceeds of approximately $328 million, prior to deducting transaction expenses, consisting of approximately $93 million from the former FLAC trust account (reflecting a final redemption rate of approximately 32 percent) and approximately $235 million from PIPE investors. The upsized and oversubscribed PIPE was co-led by Frazier Healthcare Partners and Bain Capital Life Sciences, and included new investors RA Capital Management, GMT Capital, Medicxi, Panacea Venture and other institutional investors, in addition to existing NewAmsterdam shareholders Forbion, LSP Dementia Fund and Morningside Ventures.

Advisors

Credit Suisse Securities (USA) LLC acted as lead PIPE placement agent, financial advisor and capital markets advisor to FLAC. Jefferies LLC, SVB Securities LLC and William Blair & Company, L.L.C. also acted as PIPE placement agents to FLAC and Jefferies LLC and William Blair & Company, L.L.C. also acted as financial advisor and capital markets advisor to FLAC. SVB Securities LLC acted as financial advisor and capital markets advisor to NewAmsterdam. Covington & Burling LLP acted as legal counsel to NewAmsterdam. Goodwin Procter LLP acted as legal counsel to FLAC. Kirkland & Ellis LLP acted as legal counsel to the PIPE placement agents.

About NewAmsterdam

NewAmsterdam (Nasdaq:NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients. Results from NewAmsterdam’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high-intensity statin therapy (vs. a 7% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam was founded in 2019 by the venture capital firm Forbion and John Kastelein, Chief Scientific Officer of the NewAmsterdam, and closed a $196 million (€160 million) Series A financing in January 2021 led by Forbion, Morningside Ventures and Ascendant BioCapital. In June 2022, NewAmsterdam entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease. For more information, please visit: www.newamsterdampharma.com.

Forward-Looking Statements

Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995.


Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward looking statements include, but are not limited to, statements regarding the therapeutic and curative potential of the Company’s product candidate; potential benefits of the transactions; and expectations relating to the transactions, including the Company’s expected cash runway. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; failure to realize the anticipated benefits of the transactions; risks relating to the uncertainty of the projected financial information with respect to the Company; risks related to the approval of the Company’s product candidate and the timing of expected regulatory and business milestones; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; the impact of COVID-19; global economic and political conditions, including the Russia-Ukraine conflict; the effects of competition on the Company’s future business; and those factors described in the “Risk Factors” section of the Company’s registration statement filed on Form F-4, as amended (File No. 333-266510) in connection with the transactions and other documents filed from time to time. Additional risks related to the Company’s business include, but are not limited to: uncertainty regarding outcomes of the Company’s ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company’s efforts to commercialize a product candidate; the Company’s ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company’s business; intellectual property related claims; the Company’s ability to attract and retain qualified personnel; ability to continue to source the raw materials for its product candidate. If any of these risks materialize or the Company’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. These forward-looking statements should not be relied upon as representing the Company’s assessment as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertake any obligation to update these forward-looking statements, except as required by law.

Media Contact

Spectrum Science on behalf of NewAmsterdam

Carmen Lopez

P: 1 773-306-6285

clopez@spectrumscience.com

Investor Contact

Stern Investor Relations on behalf of NewAmsterdam

Hannah Deresiewicz

P: 1 212-362-1200

hannah.deresiewicz@sternir.com

EX-101.SCH 7 flac-20221122.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 8 flac-20221122_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 flac-20221122_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Current Fiscal Year End Date Current Fiscal Year End Date Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Document Information [Table] Document Information [Table] Document Information [Line Items] Document Information [Line Items] Capital Units [Member] Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-third of one redeemable warrant [Member] Class A Common Stock Subject To Possible Redemption [Member] Class A Common Stock Subject To Possible Redemption [Member] Warrant [Member] Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 [Member] EX-101.PRE 10 flac-20221122_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 g426932gra010.jpg GRAPHIC begin 644 g426932gra010.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 22, 2022
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Nov. 22, 2022
Entity Registrant Name FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-39765
Entity Tax Identification Number 98-1562203
Entity Address, Address Line One Two Union Square
Entity Address, Address Line Two 601 Union St
Entity Address, Address Line Three Suite 3200
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98101
City Area Code 206
Local Phone Number 621-7200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Current Fiscal Year End Date --12-31
Entity Central Index Key 0001828326
Amendment Flag false
Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-third of one redeemable warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-third of one redeemable warrant
Trading Symbol FLACU
Security Exchange Name NASDAQ
Class A Common Stock Subject To Possible Redemption [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A Ordinary Shares included as part of the units
Trading Symbol FLAC
Security Exchange Name NASDAQ
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 [Member]  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50
Trading Symbol FLACW
Security Exchange Name NASDAQ
XML 13 d426932d8k_htm.xml IDEA: XBRL DOCUMENT 0001828326 2022-11-22 2022-11-22 0001828326 us-gaap:CapitalUnitsMember 2022-11-22 2022-11-22 0001828326 flac:ClassACommonStockSubjectToPossibleRedemptionMember 2022-11-22 2022-11-22 0001828326 us-gaap:WarrantMember 2022-11-22 2022-11-22 Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-third of one redeemable warrant NASDAQ NASDAQ NASDAQ --12-31 0001828326 false 8-K 2022-11-22 FRAZIER LIFESCIENCES ACQUISITION CORPORATION DE 001-39765 98-1562203 Two Union Square 601 Union St Suite 3200 Seattle WA 98101 98101 206 621-7200 false false false false FLACU Class A Ordinary Shares included as part of the units FLAC Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 FLACW true false EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-E_4)&,";C1.9816X0Z5*_?=20[,XB?+R^WRIA#,]A8+*LR%?U6-=2X4(S MEFHTR9U+^'A1#V4J(F%$/B?O(;V58&DM#Z[2R.-LP<>K^%CQ=@3#PV%^5>LX MGL=J^<.,J[F-Y^^@ M8!*;; N6/]2BX8)&%2C9UB9BIR(_O"?7L.34HER&5&OC6BQ#4> M%$K92)X+;4O%7YPI=*W>(-=N^[0=8%64N@I/=ZKP \!3@#:"'+LG[WA]&'$I M#Y:5/=H+*%96J:OO%"_/?4C^N)P YRF;U_+@ HWQXL49UDT&W(^S*"$1 M5%+8TMC$ES-B:_X@9;#BZ9,K%8N

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end XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 4 26 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:Security12bTitle, dei:SecurityExchangeName - d426932d8k.htm 7 d426932d8k.htm d426932dex101.htm d426932dex31.htm d426932dex32.htm d426932dex33.htm d426932dex991.htm flac-20221122.xsd flac-20221122_def.xml flac-20221122_lab.xml flac-20221122_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 20 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d426932d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "flac-20221122_def.xml" ] }, "inline": { "local": [ "d426932d8k.htm" ] }, "labelLink": { "local": [ "flac-20221122_lab.xml" ] }, "presentationLink": { "local": [ "flac-20221122_pre.xml" ] }, "schema": { "local": [ "flac-20221122.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 34, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 7, "total": 7 }, "keyCustom": 0, "keyStandard": 26, "memberCustom": 1, "memberStandard": 2, "nsprefix": "flac", "nsuri": "http://www.frazierlifesciencesacquisition.com/20221122", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d426932d8k.htm", "contextRef": "duration_2022-11-22_to_2022-11-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d426932d8k.htm", "contextRef": "duration_2022-11-22_to_2022-11-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "flac_ClassACommonStockSubjectToPossibleRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Common Stock Subject To Possible Redemption [Member]", "terseLabel": "Class A Common Stock Subject To Possible Redemption [Member]" } } }, "localname": "ClassACommonStockSubjectToPossibleRedemptionMember", "nsuri": "http://www.frazierlifesciencesacquisition.com/20221122", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Units [Member]", "terseLabel": "Units, each consisting of one Class A Ordinary Share, $0.0001 par value, and one-third of one redeemable warrant [Member]" } } }, "localname": "CapitalUnitsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.frazierlifesciencesacquisition.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 21 0001193125-22-292061-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-292061-xbrl.zip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�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end